COVID-19 vaccine (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "COVID-19 vaccine" in English language version.
refsWebsite
Global rank
English rank
1st place
1st place
11th place
8th place
5,225th place
4,062nd place
5th place
5th place
49th place
47th place
18th place
17th place
7th place
7th place
12th place
11th place
2,263rd place
1,687th place
102nd place
76th place
896th place
674th place
7,075th place
4,103rd place
301st place
478th place
low place
low place
low place
low place
34th place
27th place
4,540th place
3,354th place
8,771st place
5,253rd place
985th place
583rd place
99th place
77th place
9th place
13th place
36th place
33rd place
129th place
89th place
low place
6,693rd place
481st place
508th place
383rd place
320th place
40th place
58th place
low place
low place
low place
low place
low place
low place
low place
low place
433rd place
284th place
low place
low place
low place
low place
low place
low place
1,083rd place
8,125th place
low place
low place
low place
low place
low place
low place
low place
low place
low place
low place
low place
low place
low place
low place
1,943rd place
1,253rd place
low place
low place
137th place
101st place
1,241st place
1,069th place
low place
low place
5,636th place
3,692nd place
818th place
524th place
910th place
593rd place
low place
low place
low place
low place
293rd place
203rd place
211th place
915th place
low place
low place
low place
8,828th place
low place
low place
low place
low place
1,512th place
1,019th place
928th place
651st place
low place
low place
765th place
523rd place
7,303rd place
4,045th place
43rd place
161st place
low place
low place
1,948th place
1,153rd place
22nd place
19th place
1,877th place
1,129th place
388th place
265th place
8,069th place
7,681st place
139th place
108th place
3,984th place
2,622nd place
30th place
24th place
low place
low place
32nd place
21st place
3,812th place
3,173rd place
3,257th place
3,398th place
4,336th place
3,558th place
low place
low place
350th place
206th place
2,141st place
1,160th place
1,367th place
1,176th place
low place
low place
344th place
296th place
low place
low place
268th place
215th place
3,706th place
7,768th place
3,618th place
1,954th place
14th place
14th place
332nd place
246th place
abc.net.au
- "How soon after catching COVID-19 can you get it again?". ABC News. 2 May 2022. Archived from the original on 9 July 2022. Retrieved 24 June 2022.
acs.org
cen.acs.org
- Cross R (29 September 2020). "The tiny tweak behind COVID-19 vaccines". Chemical & Engineering News. Vol. 98, no. 38. Archived from the original on 16 February 2021. Retrieved 15 April 2021.
aljazeera.com
- "Investigation: Drugmaker 'bullied' Latin American nations". Al Jazeera. 11 March 2021. Archived from the original on 31 October 2021. Retrieved 15 June 2021.
ama-assn.org
- Strazewski L (9 February 2021). "Dr. Fauci: Variants reveal COVID-19 vaccination as global job". American Medical Association. Archived from the original on 10 October 2021. Retrieved 4 March 2021.
amnesty.org
- "G7 support for pharma monopolies is putting millions of lives at risk" (Press release). Amnesty International. 10 June 2021. Archived from the original on 19 October 2021. Retrieved 20 August 2021.
andina.pe
- Empresa Peruana de Servicios Editoriales S. A. EDITORA PERÚ (21 September 2021). "Peru: President suggests global agreement at UN ensuring universal access to vaccines". Andina (in Spanish). Archived from the original on 30 October 2021. Retrieved 29 September 2021.
apnews.com
- MORITSUGU K (26 October 2022). "Afraid of needles? China using inhalable COVID-19 vaccine". AP NEWS. Retrieved 2 November 2022.
- "Israel to offer 3rd COVID booster shot to older citizens". Associated Press. 29 July 2021. Archived from the original on 31 October 2021. Retrieved 16 August 2021.
apublica.org
- Muniz B, Fonseca B, Fernandes L, Pina R (15 March 2021). "Brasil registra duas vezes mais pessoas brancas vacinadas que negras" [Brazil registers twice as many white people vaccinated as black people]. Agência Pública (in Brazilian Portuguese). Archived from the original on 15 March 2021. Retrieved 28 May 2021.
archive-it.org
wayback.archive-it.org
- Blackwell T (20 April 2020). "COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work". National Post. Archived from the original on 24 April 2020. Retrieved 3 May 2020.
archive.today
- Leonhardt D (11 March 2024). "The Fourth Anniversary of the Covid Pandemic". The New York Times. Archived from the original on 11 March 2024. "Data excludes Alaska. Sources: C.D.C. Wonder; Edison Research. (Chart) By The New York Times. Source credits chart to Ashley Wu.
army.mil
wrair.army.mil
- "Phase 1 Clinical Trial of WRAIR-developed COVID-19 Vaccine Begins". 5 April 2022. Archived from the original on 11 July 2022. Retrieved 11 July 2022.
arstechnica.com
- Mole B (12 January 2024). "COVID shots protect against COVID-related strokes, heart attacks, study finds". Ars Technica. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
arxiv.org
- Arbeitman CR, Rojas P, Ojeda-May P, Garcia ME (September 2021). "The SARS-CoV-2 spike protein is vulnerable to moderate electric fields". Nature Communications. 12 (1): 5407. arXiv:2103.12733. Bibcode:2021NatCo..12.5407A. doi:10.1038/s41467-021-25478-7. PMC 8437970. PMID 34518528.
bbc.com
- "Covid: Australian vaccine abandoned over false HIV response". BBC News Online. 11 December 2020. Archived from the original on 16 January 2021. Retrieved 9 April 2023.
- Roberts M (2 December 2020). "Covid Pfizer vaccine approved for use next week in UK". BBC News Online. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
- "Covid-19 vaccinations: African nations miss WHO target". BBC. 31 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
- "Covid-19 vaccines: Why some African states can't use their vaccines". BBC News. 8 June 2021. Archived from the original on 14 November 2021. Retrieved 20 August 2021.
biopharma-reporter.com
- Byrne J (19 October 2020). "Moderna COVID-19 vaccine under rolling review process in Canada, EU". BioPharma-Reporter.com, William Reed Business Media Ltd. Archived from the original on 25 February 2021. Retrieved 25 November 2020.
bloomberg.com
- Sink J, Fabian J, Griffin R (15 May 2020). "Trump introduces 'Warp Speed' leaders to hasten COVID-19 vaccine". Bloomberg. Archived from the original on 21 May 2020. Retrieved 15 May 2020.
- Horton C (17 February 2021). "Taiwan Concerned China May Have Blocked Vaccine Purchase". Bloomberg. Archived from the original on 17 February 2021. Retrieved 17 February 2021.
bna.bh
- "Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine". Bahrain News Agency. 4 December 2020. Archived from the original on 17 December 2020. Retrieved 9 December 2020.
brazilian.report
- "U.S. pressured Brazil to ditch Russia's Sputnik V vaccine". The Brazilian Report. 15 March 2021. Archived from the original on 15 March 2021. Retrieved 21 March 2021.
britannica.com
- Rogers K (11 May 2022). "COVID-19 vaccine". Encyclopædia Britannica. Archived from the original on 12 June 2022. Retrieved 12 June 2022.
business-standard.com
- Das S (5 July 2021). "CoWIN goes global: India makes tech open source, 142 nations show interest". Business Standard India. Archived from the original on 25 March 2022. Retrieved 25 March 2022.
canada.ca
canada.ca
- "Government of Canada's research response to COVID-19". Government of Canada. 23 April 2020. Archived from the original on 13 May 2020. Retrieved 4 May 2020.
- "Use of AstraZeneca COVID-19 vaccine in younger adults" (Press release). Health Canada. 29 March 2021. Archived from the original on 11 October 2021. Retrieved 2 April 2021.
covid-vaccine.canada.ca
- "Regulatory Decision Summary – Pfizer–BioNTech COVID-19 Vaccine". Health Canada, Government of Canada. 9 December 2020. Archived from the original on 30 January 2021. Retrieved 9 December 2020.
carnegieendowment.org
- "Playing Politics with Poverty: Sisi's COVID-19 Vaccine Strategy". Carnegie Endowment for International Peace. Archived from the original on 28 February 2021. Retrieved 25 February 2021.
cbc.ca
- "COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert". CBC Radio. 8 May 2020. Archived from the original on 13 May 2020. Retrieved 8 June 2020.
cdc.gov
- "COVID-19 ACIP Vaccine Recommendations". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 3 November 2021. Retrieved 18 February 2021.
- "Understanding Viral Vector COVID-19 Vaccines". U.S. Centers for Disease Control and Prevention (CDC). 13 April 2021. Archived from the original on 13 November 2021. Retrieved 19 April 2021.
- "Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine)". U.S. Centers for Disease Control and Prevention (CDC). 3 August 2021. Archived from the original on 14 October 2019. Retrieved 8 September 2021.
- "AstraZeneca COVID-19 Vaccine (AZD1222)" (PDF). ACIP COVID-19 Emergency Meeting. AstraZeneca. 27 January 2021. Archived (PDF) from the original on 27 January 2021. Retrieved 16 April 2021.
- Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
- Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. (September 2021). "Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (37): 1284–1290. doi:10.15585/mmwr.mm7037e1. PMC 8445374. PMID 34529637.
- Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–1169. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521.
- Payne AB (2024). "Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (1): 16–23. doi:10.15585/mmwr.mm7301a4. ISSN 0149-2195. PMC 10794061. PMID 38206877. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
- "Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity". Centers for Disease Control and Prevention (CDC). 29 October 2021. Archived from the original on 4 December 2021. Retrieved 4 December 2021.
This article incorporates text from this source, which is in the public domain. - "COVID-19 Booster Shot". Centers for Disease Control and Prevention. 29 November 2021. Archived from the original on 21 August 2021. Retrieved 4 December 2021.
- "Coronavirus Disease 2019". Centers for Disease Control and Prevention (Press release). 29 March 2022. Archived from the original on 1 September 2022. Retrieved 22 August 2022.
- "Omicron Variant: What You Need to Know". Centers for Disease Control and Prevention. 20 December 2021. Archived from the original on 27 January 2022. Retrieved 27 January 2022.
- "Additional Dose of mRNA COVID‑19 Vaccine for Patients Who Are Immunocompromised". U.S. Centers for Disease Control and Prevention (CDC). 13 August 2021. Archived from the original on 7 October 2021. Retrieved 16 August 2021.
- Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR Morb Mortal Wkly Rep. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 9 June 2021.
- "When You've Been Fully Vaccinated". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 28 July 2021. Retrieved 29 April 2021.
chictr.org.cn
- Chen W, Al Kaabi N (July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
clinicaltrials.gov
- "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". ClinicalTrials.gov. 30 April 2020. NCT04368728. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". ClinicalTrials.gov. 14 July 2020. NCT04470427. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
- "Investigating a Vaccine Against COVID-19". ClinicalTrials.gov. 26 May 2020. NCT04400838. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "A Study of Ad26.COV2.S in Adults". 4 August 2020. Archived from the original on 16 September 2020. Retrieved 23 August 2020.
- "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". US National Library of Medicine. Archived from the original on 26 September 2020.
- "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
- "Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactivated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults". U.S. National Library of Medicine. 30 December 2020. Archived from the original on 14 February 2021. Retrieved 11 January 2021.
- "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)". ClinicalTrials.gov. 22 September 2020. NCT04368988. Archived from the original on 29 June 2021. Retrieved 16 November 2020.
- "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults". ClinicalTrials.gov. 3 August 2020. NCT04495933. Archived from the original on 11 October 2020. Retrieved 4 August 2020.
- "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant". ClinicalTrials.gov. 30 April 2020. NCT04368988. Archived from the original on 14 July 2020. Retrieved 14 July 2020.
- "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". ClinicalTrials.gov. 7 April 2020. NCT04336410. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- Chang LJ (March 2020). "Safety and Immunity of Covid-19 aAPC Vaccine". ClinicalTrials.gov. NCT04299724. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine". ClinicalTrials.gov. February 2020. NCT04276896. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults". ClinicalTrials.gov. November 2020. NCT04608305. Archived from the original on 3 May 2021. Retrieved 2 January 2021.
- "Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection". ClinicalTrials.gov. 30 December 2020. Archived from the original on 13 May 2022. Retrieved 5 September 2022.
- "Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19". ClinicalTrials.gov. 16 August 2021. Archived from the original on 18 June 2022. Retrieved 5 September 2022.
- "First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers". clinicaltrials.gov. Retrieved 30 August 2024.
- "Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers". clinicaltrials.gov. Retrieved 30 August 2024.
- "Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a". clinicaltrials.gov. National Institutes of Health. Retrieved 30 August 2024.
clinicaltrialsregister.eu
- "A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults". EU Clinical Trials Register. 14 April 2020. EudraCT 2020-001038-36. Archived from the original on 22 April 2020. Retrieved 22 April 2020.
- "A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19". EU Clinical Trials Register. 21 April 2020. EudraCT 2020-001228-32. Archived from the original on 5 October 2020. Retrieved 3 August 2020.
cnbc.com
- Lovelace Jr B (19 December 2020). "FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution". CNBC. Archived from the original on 26 January 2021. Retrieved 19 December 2020.
- Kimball S. "CDC recommends fourth Pfizer and Moderna Covid vaccine doses for people age 50 and older". CNBC. Archived from the original on 3 September 2022. Retrieved 22 August 2022.
- Macias AM, Breuninger K, Franck (5 May 2021). "U.S. backs waiving patent protections for Covid vaccines, citing global health crisis". CNBC. Archived from the original on 5 May 2021. Retrieved 5 May 2021.
cnn.com
- Howard J, Stracqualursi V (18 June 2020). "Fauci warns of 'anti-science bias' being a problem in US". CNN. Archived from the original on 21 June 2020. Retrieved 21 June 2020.
- Kuznia R, Polglase K, Mezzofiore G (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. Archived from the original on 13 May 2020. Retrieved 2 May 2020.
- Holcombe M, Waldrop T (11 September 2021). "CDC study: Unvaccinated 11 times more likely to die from Covid-19". CNN. Retrieved 11 September 2021.
- Bergmark E, Wierson A (26 February 2021). "Opinion: Without a global vaccine plan, coronavirus variants could lead to untold number of deaths". CNN. Archived from the original on 19 October 2021. Retrieved 4 March 2021.
cnnbrasil.com.br
- Barcellos R (13 May 2021). "Carlos Murillo diz que cláusulas criticadas pelo Brasil valem em 110 países" [Carlos Murillo says critical clauses for Brazil are valid in 110 countries]. CNN Brasil (in Portuguese). Archived from the original on 28 June 2021. Retrieved 15 June 2021.
cornell.edu
allianceforscience.cornell.edu
- Lynas M (20 April 2020). "COVID: Top 10 current conspiracy theories". Alliance for Science. Retrieved 4 October 2021.
ctri.nic.in
- "A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects". India: Clinical Trials Registry. 15 December 2020. CTRI/2020/07/026352. Archived from the original on 22 November 2020.
curevac.com
- "CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60". CureVac (Press release). 30 June 2021. Archived from the original on 12 October 2021. Retrieved 2 July 2021.
dcvmn.org
doi.org
- Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. PMC 7749790. PMID 33341119.
- Subbarao K (July 2021). "The success of SARS-CoV-2 vaccines and challenges ahead". Cell Host & Microbe. 29 (7): 1111–1123. doi:10.1016/j.chom.2021.06.016. PMC 8279572. PMID 34265245.
- Dodaran MS, Banihashemi SR, Es-haghi A, Mehrabadi MH, Nofeli M, Mokarram AR, et al. (16 February 2023). "Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial". Vaccines. 11 (2): 455. doi:10.3390/vaccines11020455. PMC 9961243. PMID 36851334.
- Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, et al. (January 2023). "Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children". International Journal of Infectious Diseases. 126: 164–173. doi:10.1016/j.ijid.2022.11.016. PMC 9673084. PMID 36403819. Retrieved 28 June 2024.
- Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Van Noorden R (December 2021). "How COVID vaccines shaped 2021 in eight powerful charts". Nature. 600 (7890): 580–583. Bibcode:2021Natur.600..580M. doi:10.1038/d41586-021-03686-x. PMID 34916666. S2CID 245262732.
- Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (June 2022). "Global impact of the first year of COVID-19 vaccination: a mathematical modelling study". The Lancet Infectious Diseases. 22 (9): 1293–1302. doi:10.1016/s1473-3099(22)00320-6. PMC 9225255. PMID 35753318.
- Wang H, Xu R, Qu S, Schwartz M, Adams A, Chen X (October 2021). "Health inequities in COVID-19 vaccination among the elderly: Case of Connecticut". Journal of Infection and Public Health. 14 (10): 1563–1565. doi:10.1016/j.jiph.2021.07.013. PMC 8491089. PMID 34326008. S2CID 236515442.
- Mullard A (November 2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811.
- So AD, Woo J (December 2020). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". BMJ. 371: m4750. doi:10.1136/bmj.m4750. PMC 7735431. PMID 33323376.
- Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. ISSN 0066-4219. PMID 34637324. S2CID 238747462.
- Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
- Cavanagh D (December 2003). "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus". Avian Pathology. 32 (6): 567–582. doi:10.1080/03079450310001621198. PMC 7154303. PMID 14676007.
- Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, et al. (December 2003). "Effects of a SARS-associated coronavirus vaccine in monkeys". Lancet. 362 (9399): 1895–1896. doi:10.1016/S0140-6736(03)14962-8. PMC 7112457. PMID 14667748.
- Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, et al. (October 2014). "Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice". Vaccine. 32 (45): 5975–5982. doi:10.1016/j.vaccine.2014.08.058. PMC 7115510. PMID 25192975.
- Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, et al. (February 2005). "Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice". The Journal of Infectious Diseases. 191 (4): 507–514. doi:10.1086/427242. PMC 7110081. PMID 15655773.
- Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, et al. (September 2005). "Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins". Journal of Virological Methods. 128 (1–2): 21–28. doi:10.1016/j.jviromet.2005.03.021. PMC 7112802. PMID 15885812.
- Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, et al. (March 2006). "Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters". The Journal of Infectious Diseases. 193 (5): 685–692. doi:10.1086/500143. PMC 7109703. PMID 16453264.
- Jiang S, Lu L, Du L (January 2013). "Development of SARS vaccines and therapeutics is still needed". Future Virology. 8 (1): 1–2. doi:10.2217/fvl.12.126. PMC 7079997. PMID 32201503.
- Shehata MM, Gomaa MR, Ali MA, Kayali G (June 2016). "Middle East respiratory syndrome coronavirus: a comprehensive review". Frontiers of Medicine. 10 (2): 120–136. doi:10.1007/s11684-016-0430-6. PMC 7089261. PMID 26791756.
- Butler D (October 2012). "SARS veterans tackle coronavirus". Nature. 490 (7418): 20. Bibcode:2012Natur.490...20B. doi:10.1038/490020a. PMID 23038444.
- Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. (September 2019). "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial". The Lancet. Infectious Diseases. 19 (9): 1013–1022. doi:10.1016/S1473-3099(19)30266-X. PMC 7185789. PMID 31351922.
- Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS (2019). "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus". Frontiers in Microbiology. 10: 1781. doi:10.3389/fmicb.2019.01781. PMC 6688523. PMID 31428074.
- Sharma O, Sultan AA, Ding H, Triggle CR (14 October 2020). "A Review of the Progress and Challenges of Developing a Vaccine for COVID-19". Frontiers in Immunology. 11: 585354. doi:10.3389/fimmu.2020.585354. PMC 7591699. PMID 33163000.
- Bok K, Sitar S, Graham BS, Mascola JR (August 2021). "Accelerated COVID-19 vaccine development: milestones, lessons, and prospects". Immunity. 54 (8): 1636–1651. doi:10.1016/j.immuni.2021.07.017. PMC 8328682. PMID 34348117.
- Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. (August 2021). "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses". Nature. 596 (7870): 109–113. Bibcode:2021Natur.596..109T. doi:10.1038/s41586-021-03738-2. PMC 8935394. PMID 34182569.
- Flanagan KL, Best E, Crawford NW, Giles M, Koirala A, Macartney K, et al. (2020). "Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines". Frontiers in Immunology. 11: 579250. doi:10.3389/fimmu.2020.579250. PMC 7566192. PMID 33123165.
- Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
- Arbeitman CR, Rojas P, Ojeda-May P, Garcia ME (September 2021). "The SARS-CoV-2 spike protein is vulnerable to moderate electric fields". Nature Communications. 12 (1): 5407. arXiv:2103.12733. Bibcode:2021NatCo..12.5407A. doi:10.1038/s41467-021-25478-7. PMC 8437970. PMID 34518528.
- Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. (June 2020). "Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals". Cell. 181 (7): 1489–1501.e15. doi:10.1016/j.cell.2020.05.015. PMC 7237901. PMID 32473127.
- Dutta NK, Mazumdar K, Gordy JT (June 2020). Dutch RE (ed.). "The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development". Journal of Virology. 94 (13). doi:10.1128/JVI.00647-20. PMC 7307180. PMID 32546606.
- Nikolaidis M, Markoulatos P, Van de Peer Y, Oliver SG, Amoutzias GD (October 2021). Hepp C (ed.). "The neighborhood of the Spike gene is a hotspot for modular intertypic homologous and non-homologous recombination in Coronavirus genomes". Molecular Biology and Evolution. 39: msab292. doi:10.1093/molbev/msab292. PMC 8549283. PMID 34638137.
- Amoutzias GD, Nikolaidis M, Tryfonopoulou E, Chlichlia K, Markoulatos P, Oliver SG (January 2022). "The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2". Viruses. 14 (1): 78. doi:10.3390/v14010078. PMC 8778387. PMID 35062282.
- Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–06. doi:10.1038/d41573-020-00073-5. PMID 32273591.
- Diamond MS, Pierson TC (May 2020). "The Challenges of Vaccine Development against a New Virus during a Pandemic". Cell Host & Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
- Krammer F (October 2020). "SARS-CoV-2 vaccines in development". Nature. 586 (7830): 516–527. Bibcode:2020Natur.586..516K. doi:10.1038/s41586-020-2798-3. PMID 32967006. S2CID 221887746.
- Park KS, Sun X, Aikins ME, Moon JJ (February 2021). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews. 169: 137–151. doi:10.1016/j.addr.2020.12.008. ISSN 0169-409X. PMC 7744276. PMID 33340620.
- Kowalski PS, Rudra A, Miao L, Anderson DG (April 2019). "Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery". Molecular Therapy. 27 (4): 710–728. doi:10.1016/j.ymthe.2019.02.012. PMC 6453548. PMID 30846391.
- Verbeke R, Lentacker I, De Smedt SC, Dewitte H (October 2019). "Three decades of messenger RNA vaccine development". Nano Today. 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. S2CID 202221207. Archived from the original on 9 October 2021. Retrieved 17 January 2021.
- Moghimi SM (March 2021). "Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines". Molecular Therapy. 29 (3): 898–900. doi:10.1016/j.ymthe.2021.01.030. PMC 7862013. PMID 33571463.
- O'Reilly P (May 2020). "A Phase III study to investigate a vaccine against COVID-19". ISRCTN Registry. doi:10.1186/ISRCTN89951424.
- Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. (August 2020). "A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge". Nat Commun. 11 (1): 4081. Bibcode:2020NatCo..11.4081W. doi:10.1038/s41467-020-17972-1. PMC 7427994. PMID 32796842.
- Petrovsky N, Aguilar JC (October 2004). "Vaccine adjuvants: current state and future trends". Immunology and Cell Biology. 82 (5): 488–496. doi:10.1111/j.0818-9641.2004.01272.x. PMID 15479434. S2CID 154670.
- Mudgal R, Nehul S, Tomar S (December 2020). "Prospects for mucosal vaccine: shutting the door on SARS-CoV-2". Human Vaccines & Immunotherapeutics. 16 (12): 2921–2931. doi:10.1080/21645515.2020.1805992. PMC 7544966. PMID 32931361.
- Rhee JH (2020). "Current and New Approaches for Mucosal Vaccine Delivery". Mucosal Vaccines. Elsevier. pp. 325–356. doi:10.1016/b978-0-12-811924-2.00019-5. ISBN 9780128119242. PMC 7149853.
- Waltz E (September 2022). "China and India approve nasal COVID vaccines - are they a game changer?". Nature. 609 (7927): 450. Bibcode:2022Natur.609..450W. doi:10.1038/d41586-022-02851-0. PMID 36071228. S2CID 252121594.
- Dhama K, Dhawan M, Tiwari R, Emran TB, Mitra S, Rabaan AA, et al. (November 2022). "COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges". Human Vaccines & Immunotherapeutics. 18 (5): 2045853. doi:10.1080/21645515.2022.2045853. PMC 8935456. PMID 35258416.
- Nistor GI, Dillman RO, Robles RM, Langford JL, Poole AJ, Sofro MA, et al. (August 2022). "A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses". Human Vaccines & Immunotherapeutics. 18 (6): 2100189. doi:10.1080/21645515.2022.2100189. PMC 9746383. PMID 36018753.
- Ober Shepherd BL, Scott PT, Hutter JN, Lee C, McCauley MD, Guzman I, et al. (EID-030 Study Group) (June 2024). "SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial". The Lancet. Microbe. 5 (6): e581–e593. doi:10.1016/S2666-5247(23)00410-X. PMC 11192176. PMID 38761816.
- Tregoning JS, Russell RF, Kinnear E (March 2018). "Adjuvanted influenza vaccines". Human Vaccines & Immunotherapeutics. 14 (3): 550–564. doi:10.1080/21645515.2017.1415684. PMC 5861793. PMID 29232151.
- Wang J, Peng Y, Xu H, Cui Z, Williams RO (August 2020). "The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation". AAPS PharmSciTech. 21 (6): 225. doi:10.1208/s12249-020-01744-7. PMC 7405756. PMID 32761294.
- Simpson S, Kaufmann MC, Glozman V, Chakrabarti A (May 2020). "Disease X: accelerating the development of medical countermeasures for the next pandemic". The Lancet. Infectious Diseases. 20 (5): e108–15. doi:10.1016/S1473-3099(20)30123-7. PMC 7158580. PMID 32197097.
- Zabaleta N, Dai W, Bhatt U, Hérate C, Maisonnasse P, Chichester JA, et al. (August 2021). "An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates". Cell Host & Microbe. 29 (9): 1437–1453.e8. doi:10.1016/j.chom.2021.08.002. PMC 8346325. PMID 34428428. S2CID 231676030.
- Thorp HH (March 2020). "Underpromise, overdeliver". Science. 367 (6485): 1405. Bibcode:2020Sci...367.1405T. doi:10.1126/science.abb8492. PMID 32205459. S2CID 214628067.
- Cohen J (June 2020). "Pandemic vaccines are about to face the real test". Science. 368 (6497): 1295–96. Bibcode:2020Sci...368.1295C. doi:10.1126/science.368.6497.1295. PMID 32554572. S2CID 219911109.
- Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J (August 2013). "Vaccine hesitancy: an overview". Human Vaccines & Immunotherapeutics. 9 (8): 1763–73. doi:10.4161/hv.24657. PMC 3906279. PMID 23584253.
- Cohen J (May 2020). "U.S. 'Warp Speed' vaccine effort comes out of the shadows". Science. 368 (6492): 692–93. Bibcode:2020Sci...368..692C. doi:10.1126/science.368.6492.692. PMID 32409451.
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (June 2021). "Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination". The New England Journal of Medicine. 384 (22): 2092–101. doi:10.1056/NEJMoa2104840. PMC 8095372. PMID 33835769.
- Cines DB, Bussel JB (June 2021). "SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia". The New England Journal of Medicine. 384 (23): 2254–2256. doi:10.1056/NEJMe2106315. PMC 8063912. PMID 33861524.
- Liu Y, Shao Z, Wang H (December 2021). "SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia". Thrombosis Research. 209: 75–79. doi:10.1016/j.thromres.2021.12.002. PMC 8647389. PMID 34894531.
- Klok FA, Pai M, Huisman MV, Makris M (November 2021). "Vaccine-induced immune thrombotic thrombocytopenia". The Lancet. Haematology. 9 (1): e73–e80. doi:10.1016/S2352-3026(21)00306-9. PMC 8585488. PMID 34774202.
Although initially several terms were used to describe the syndrome … the term that has gained widespread use is vaccine-induced immune thrombotic thrombocytopenia (VITT). Thrombosis with thrombocytopenia syndrome has also been used, but it is a more general term that can be caused by other conditions
- Warkentin TE, Pai M (October 2021). "Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res 2021 in press". Thrombosis Research. 207: 158–160. doi:10.1016/j.thromres.2021.10.007. PMID 34757250. S2CID 239574011.
We believe the name "VITT" works well … the term clearly denotes the key features of the disorder … provides a useful mnemonic for disease recognition in the usual sequence of events … need not mandate that thrombosis be present … "TTS" … has limited clinical utility, since many conditions … present with the duad of thrombosis and thrombocytopenia
- Long B, Bridwell R, Gottlieb M (November 2021). "Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines". The American Journal of Emergency Medicine. 49: 58–61. doi:10.1016/j.ajem.2021.05.054. PMC 8143907. PMID 34062319.
- Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. PMID 32273591.
- Gates B (February 2020). "Responding to Covid-19: A once-in-a-century pandemic?". The New England Journal of Medicine. 382 (18): 1677–79. doi:10.1056/nejmp2003762. PMID 32109012.
- Fauci AS, Lane HC, Redfield RR (March 2020). "Covid-19: Navigating the uncharted". The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
- Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–668. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
- Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). "Ensuring global access to COVID‑19 vaccines". Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778.
CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
- Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
- Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
- Yang ZR, Jiang YW, Li FX, Liu D, Lin TF, Zhao ZY, et al. (April 2023). "Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials". The Lancet. Microbe. 4 (4): e236–e246. doi:10.1016/S2666-5247(22)00390-1. PMC 9974155. PMID 36868258.
- Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. (September 2021). "Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (37): 1284–1290. doi:10.15585/mmwr.mm7037e1. PMC 8445374. PMID 34529637.
- Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–1169. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521.
- Lee AR, Wong SY, Chai LY, Lee SC, Lee MX, Muthiah MD, et al. (March 2022). "Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis". BMJ. 376: e068632. doi:10.1136/bmj-2021-068632. PMC 8889026. PMID 35236664.
- Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL (August 2021). "Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies". Cancer Cell. 39 (8): 1031–1033. doi:10.1016/j.ccell.2021.07.012. PMC 8295014. PMID 34331856.
- Stein C, Nassereldine H, Sorensen RJ, Amlag JO, Bisignano C, Byrne S, et al. (February 2023). "Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis". The Lancet. 401 (10379): 833–842. doi:10.1016/S0140-6736(22)02465-5. ISSN 0140-6736. PMC 9998097. PMID 36930674.
- Payne AB (2024). "Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (1): 16–23. doi:10.15585/mmwr.mm7301a4. ISSN 0149-2195. PMC 10794061. PMID 38206877. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
- Català M, Mercadé-Besora N, Kolde R, Trinh NT, Roel E, Burn E, et al. (March 2024). "The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia". The Lancet. Respiratory Medicine. 12 (3): 225–236. doi:10.1016/s2213-2600(23)00414-9. PMID 38219763.
- "Vaccines reduce the risk of long COVID". NIHR Evidence. 2024. doi:10.3310/nihrevidence_63203.
- Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. (December 2021). "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months". The New England Journal of Medicine. 385 (24): e84. doi:10.1056/NEJMoa2114583. PMC 8522797. PMID 34614326.
- Wang R, Chen J, Wei GW (December 2021). "Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America" (PDF). The Journal of Physical Chemistry Letters. 12 (49): 11850–11857. doi:10.1021/acs.jpclett.1c03380. PMC 8672435. PMID 34873910. Archived (PDF) from the original on 18 December 2021. Retrieved 27 January 2022.
- Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. (February 2022). "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies". Nature. 602 (7898): 657–663. doi:10.1038/d41586-021-03796-6. PMC 8866119. PMID 35016194. S2CID 245455422.
- Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. (February 2022). "Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2". Nature. 602 (7898): 676–681. doi:10.1038/d41586-021-03826-3. PMID 35016198. S2CID 245462866.
- Mohsin M, Mahmud S (May 2022). "Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity". Medicine. 101 (19): e29165. doi:10.1097/MD.0000000000029165. PMC 9276130. PMID 35583528. S2CID 248858919.
- Shin DH, Smith DM, Choi JY (2022). "SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask". Yonsei Medical Journal. 63 (11): 977–983. doi:10.3349/ymj.2022.0383. PMC 9629902. PMID 36303305.
- Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. (February 2022). "Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study". The Lancet. Infectious Diseases. 22 (2): 183–195. doi:10.1016/S1473-3099(21)00648-4. PMC 8554486. PMID 34756186.
- Callaway E (October 2021). "Mix-and-match COVID vaccines ace the effectiveness test". Nature. doi:10.1038/d41586-021-02853-4. PMID 34675430. S2CID 239455075.
- Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N (April 2022). "COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts". Journal of Medical Virology. 94 (4): 1294–1299. doi:10.1002/jmv.27463. PMC 8661746. PMID 34796525.
- Al-Haideri MT, Mannani R, Kaboli R, Gharebakhshi F, Darvishzadehdeldari S, Tahmasebi S, et al. (August 2023). "The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence". Transplant Immunology. 79: 101858. doi:10.1016/j.trim.2023.101858. PMC 10205646. PMID 37236514.
- "A pause in methotrexate treatment boosted the immune response to the COVID-19 vaccine". NIHR Evidence. National Institute for Health and Care Research. 26 January 2023. doi:10.3310/nihrevidence_56391.
- Wroński J, Ciechomska M, Kuca-Warnawin E (September 2023). "Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 165: 115254. doi:10.1016/j.biopha.2023.115254. PMID 37542854.
- Imran M, Ali S, Ibrahim AA, Amjad A, Tanveer A, Khalil S, et al. (July 2024). "Effect of methotrexate hold on COVID-19 vaccine response in the patients with autoimmune inflammatory disorders: a systematic review and meta-analysis". Clinical Rheumatology. 43 (7): 2203–2214. doi:10.1007/s10067-024-07013-3. PMID 38802670.
- Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Francis A, et al. (February 2024). "Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial". The Lancet. Rheumatology. 6 (2): e92–e104. doi:10.1016/S2665-9913(23)00298-9. PMID 38267107.
- Kouhpayeh H, Ansari H (August 2022). "Adverse events following COVID-19 vaccination: A systematic review and meta-analysis". International Immunopharmacology. 109: 108906. doi:10.1016/j.intimp.2022.108906. PMC 9148928. PMID 35671640.
- Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, et al. (December 2022). "Efficacy and safety of COVID-19 vaccines". The Cochrane Database of Systematic Reviews. 12 (12): CD015477. doi:10.1002/14651858.CD015477. PMC 9726273. PMID 36473651.
- Haas JW, Bender FL, Ballou S, Kelley JM, Wilhelm M, Miller FG, et al. (January 2022). "Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis". JAMA Network Open. 5 (1): e2143955. doi:10.1001/jamanetworkopen.2021.43955. PMC 8767431. PMID 35040967.
- Huang Z, Su Y, Zhang T, Xia N (February 2022). "A review of the safety and efficacy of current COVID-19 vaccines". Frontiers of Medicine. 16 (1): 39–55. doi:10.1007/s11684-021-0893-y. PMC 8815389. PMID 35122210.
- Tu W, Gierada DS, Joe BN (May 2021). "COVID-19 Vaccination-Related Lymphadenopathy: What To Be Aware Of". Radiology. Imaging Cancer. 3 (3): e210038. doi:10.1148/rycan.2021210038. PMC 8049171. PMID 33874733.
- Male V (January 2022). "Menstruation and covid-19 vaccination". BMJ. 376: o142. doi:10.1136/bmj.o142. hdl:10044/1/94577. PMID 35082132. S2CID 246287912.
- Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. (October 2021). "Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military". JAMA Cardiology. 6 (10): 1202–06. doi:10.1001/jamacardio.2021.2833. PMC 8243257. PMID 34185045.
- Frontera JA, Tamborska AA, Doheim MF, Garcia-Azorin D, Gezegen H, Guekht A, et al. (March 2022). "Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS". Annals of Neurology. 91 (6): 756–771. doi:10.1002/ana.26339. PMC 9082459. PMID 35233819.
- Altmann DM, Boyton RJ (March 2022). "COVID-19 vaccination: The road ahead". Science. 375 (6585): 1127–1132. Bibcode:2022Sci...375.1127A. doi:10.1126/science.abn1755. PMID 35271316. S2CID 247384207.
- Basso C (October 2022). "Myocarditis". The New England Journal of Medicine. 387 (16): 1488–1500. doi:10.1056/NEJMra2114478. hdl:11577/3479721. PMID 36260793. S2CID 240234869.
- Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. (December 2021). "Myocarditis after Covid-19 Vaccination in a Large Health Care Organization". The New England Journal of Medicine. 385 (23): 2132–2139. doi:10.1056/NEJMoa2110737. PMC 8531986. PMID 34614329. S2CID 238421512.
- Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. (September 2022). "Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex". Circulation. 146 (10): 743–754. doi:10.1161/CIRCULATIONAHA.122.059970. PMC 9439633. PMID 35993236.
- Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. (April 2022). "New-onset autoimmune phenomena post-COVID-19 vaccination". Immunology. 165 (4): 386–401. doi:10.1111/imm.13443. PMID 34957554. S2CID 245522029.
- Jafari Z, Kolb BE, Mohajerani MH (March 2022). "Hearing Loss, Tinnitus, and Dizziness in COVID-19: A Systematic Review and Meta-Analysis". The Canadian Journal of Neurological Sciences. 49 (2): 184–195. doi:10.1017/cjn.2021.63. PMC 8267343. PMID 33843530.
- Slomski A (May 2022). "Studies Examine Risk of Hearing Loss After COVID-19 Vaccination". JAMA. 327 (17): 1641. doi:10.1001/jama.2022.6719. PMID 35503358. S2CID 248502943.
- Dorney I, Bobak L, Otteson T, Kaelber DC (September 2022). "Prevalence of New-Onset Tinnitus after COVID-19 Vaccination with Comparison to Other Vaccinations". The Laryngoscope. 133 (7): 1722–1725. doi:10.1002/lary.30395. PMC 9539087. PMID 36098476.
- Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. (2021). "A global database of COVID-19 vaccinations". Nature Human Behaviour. 5 (7): 947–953. doi:10.1038/s41562-021-01122-8. PMID 33972767.
- Gates B (April 2020). "Responding to Covid-19 - A Once-in-a-Century Pandemic?". The New England Journal of Medicine. 382 (18): 1677–1679. doi:10.1056/nejmp2003762. PMID 32109012.
- The Lancet Infectious Diseases Editors (September 2021). "COVID-19 vaccine equity and booster doses". The Lancet Infectious Diseases. 21 (9): 1193. doi:10.1016/S1473-3099(21)00486-2. PMC 8360703. PMID 34391506.
- Mahase E (July 2021). "Covid-19: Countries dump vaccines as demand slumps and sharing proves difficult". BMJ. 374: n1893. doi:10.1136/bmj.n1893. PMID 34315725. S2CID 236457553.
- "The WHO is right to call a temporary halt to COVID vaccine boosters". Nature. 596 (7872): 317. August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262.
- Baraniuk C (February 2021). "Covid-19: How the UK vaccine rollout delivered success, so far". BMJ. 372: n421. doi:10.1136/bmj.n421. PMID 33602672. S2CID 231946710.
- Hunziker P (July 2021). "Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit". Precision Nanomedicine. 4 (3): 805–820. doi:10.33218/001c.26101. Archived from the original on 9 October 2021. Retrieved 16 August 2021.
- Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR Morb Mortal Wkly Rep. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 9 June 2021.
dw.com
- "Australian vaccine trials stopped due to HIV false positives". Deutsche Welle. 11 December 2020. Archived from the original on 26 January 2021. Retrieved 9 January 2023.
- "Treating Post-Vac-Syndrome". Deutsche Welle. 11 October 2022. Archived from the original on 17 April 2023.
euobserver.com
- Sánchez Nicolás E (11 June 2021). "Pressure builds on EU to back WTO vaccine-patent waiver". EUobserver. Archived from the original on 19 October 2021. Retrieved 14 June 2021.
europa.eu
ema.europa.eu
- "EMA recommends first COVID-19 vaccine for authorisation in the EU". European Medicines Agency (EMA) (Press release). 21 December 2020. Archived from the original on 30 January 2021. Retrieved 21 December 2020.
- "VidPrevtyn Beta". European Medicines Agency (EMA). 4 November 2022. Archived from the original on 11 November 2022. Retrieved 12 November 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "EMA recommends approval of VidPrevtyn Beta as a COVID-19 booster vaccine". European Medicines Agency (EMA) (Press release). 10 November 2022. Archived from the original on 12 November 2022. Retrieved 12 November 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Bimervax EPAR". European Medicines Agency. 5 April 2023. Archived from the original on 8 April 2023. Retrieved 9 April 2023.
- "COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Retrieved 14 October 2024.
- "Vaccines: The Emergency Authorisation Procedure". European Medicines Agency (EMA). 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
- "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR". European Medicines Agency (EMA). 25 January 2021. Archived from the original on 21 April 2021. Retrieved 16 April 2021.
The name of the vaccine was changed to Vaxzevria on 25 March 2021.
Vaxzevria (COVID‑19 Vaccine (ChAdOx1-S recombinant) EMA/182334/2021 Archived 15 April 2021 at the Wayback Machine Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. - "COVID-19 vaccine safety update: Vaxzevria" (PDF). European Medicines Agency (EMA). 28 March 2021. Archived (PDF) from the original on 13 April 2021. Retrieved 31 March 2021.
- Medical Director of AstraZeneca AB (13 April 2021). "Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia" (PDF). European Medicines Agency (EMA). Archived (PDF) from the original on 18 July 2022. Retrieved 13 April 2021.
- "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024". European Medicines Agency (EMA). 18 October 2024. Retrieved 21 October 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "World Health Organization (WHO)". 17 September 2018. Archived from the original on 4 October 2023. Retrieved 19 September 2023.
- COVID-19 vaccines safety update (PDF) (Report). Archived (PDF) from the original on 3 August 2022. Retrieved 6 September 2022.
- "EMA recommends standard marketing authorizations for Comirnaty and Spikevax COVID-19 vaccines". European Medicines Agency. 16 September 2022. Archived from the original on 16 September 2022. Retrieved 7 October 2022.
ec.europa.eu
- "Safe COVID-19 vaccines for Europeans". European Commission. Archived from the original on 4 November 2021. Retrieved 19 February 2021.
- "Questions and Answers: COVID-19 vaccination in the EU". European Commission. 21 December 2020. Archived from the original on 29 January 2021. Retrieved 21 December 2020.
- "Questions and Answers: Conditional Marketing Authorisation of COVID-19 Vaccines in the EU". European Commission. 11 December 2020. Question: What is the difference in liability between EU Conditional Marketing Authorisation vs Emergency Use Authorisations?. Archived from the original on 4 October 2021. Retrieved 29 December 2020.
ecdc.europa.eu
- "WHO/ECDC: Nearly half a million lives saved by COVID-19 vaccination in less than a year". 25 November 2021.
europarl.europa.eu
- Haahr T (7 September 2020). "COVID-19: MEPs want safe vaccines, full transparency and liability for companies". European Parliament. Ms. Gallina stressed negotiations with companies had been difficult but underlined that those companies developing and manufacturing COVID-19 vaccines would indeed be liable according to current laws, and if something goes wrong, they could be taken to court. This also goes for compensation for hidden defects. Archived from the original on 13 October 2021. Retrieved 29 December 2020.
factcheck.org
- Gore D (9 February 2022). "Latest CDC Data: Unvaccinated Adults 97 Times More Likely to Die from COVID-19 Than Boosted Adults". FactCheck.org. Retrieved 11 February 2022.
- McDonald J (23 December 2021). "Increase in COVID-19 VAERS Reports Due To Reporting Requirements, Intense Scrutiny of Widely Given Vaccines". FactCheck.org. Archived from the original on 20 May 2022. Retrieved 20 May 2022.
- Gore D (10 May 2021). "Exploring the legality of COVID-19 vaccine mandates". factcheck.org. Retrieved 4 October 2021.
farsnews.ir
- "FarsNews Agency Iran Licenses Emergency Injection of Home-Made Anti-Coronavirus Vaccine". Fars News Agency. 14 June 2021. Archived from the original on 9 October 2021. Retrieved 25 August 2021.
faz.net
m.faz.net
- "Corona-Impfschäden: Uniklinik Marburg öffnet eigene Ambulanz" [Corona vaccine damage: Marburg University Hospital opens its own outpatient clinic]. Frankfurter Allgemeine Zeitung GmbH (in German). 3 April 2023. Archived from the original on 8 March 2024.
fda.gov
- "Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024". U.S. Food and Drug Administration (FDA). 5 June 2024. Retrieved 19 June 2024. This article incorporates text from this source, which is in the public domain.
- "The drug development process". U.S. Food and Drug Administration (FDA). 4 January 2018. Archived from the original on 22 February 2020. Retrieved 12 April 2020.
- Marks P. "Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine". Archived from the original on 20 May 2021. Retrieved 13 April 2021.
- "Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals". U.S. Food and Drug Administration. 5 May 2022. Archived from the original on 7 May 2022. Retrieved 7 May 2022.
- "FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 17 March 2021. Retrieved 18 December 2020.
- "COVID-19 Vaccine Boosters". U.S. Food and Drug Administration (FDA). 27 September 2022. Archived from the original on 8 October 2022. Retrieved 8 October 2022.
- "Moderna COVID-19 Vaccines". U.S. Food and Drug Administration (FDA). 7 October 2022. Archived from the original on 7 October 2022. Retrieved 8 October 2022.
- "Pfizer-BioNTech COVID-19 Vaccines". U.S. Food and Drug Administration (FDA). 3 October 2022. Archived from the original on 8 October 2022. Retrieved 8 October 2022.
- "Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023". U.S. Food and Drug Administration (FDA). 15 June 2023. Archived from the original on 17 June 2023. Retrieved 16 June 2023. This article incorporates text from this source, which is in the public domain.
- Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the U.S. (PDF) (Report). U.S. Food and Drug Administration (FDA). 16 June 2023. Archived from the original on 16 June 2023. Retrieved 16 June 2023.
- "Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024". U.S. Food and Drug Administration (FDA). 5 June 2024. Archived from the original on 18 June 2024. Retrieved 19 June 2024. This article incorporates text from this source, which is in the public domain.
fiercebiotech.com
- LaHucik K (17 June 2021). "U.S. injects $3B-plus into COVID-19 research to develop antiviral pill within a year". Fierce Biotech. Archived from the original on 9 October 2021. Retrieved 11 July 2021.
flgov.com
- "Governor Ron DeSantis Petitions Florida Supreme Court for Statewide Grand Jury on COVID-19 Vaccines and Announces Creation of the Public Health Integrity Committee". www.flgov.com. Archived from the original on 14 December 2022. Retrieved 14 December 2022.
fortune.com
- "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective". Fortune. Archived from the original on 8 August 2021. Retrieved 28 February 2021.
france24.com
- "WHO slams wealthy nations' rush towards Covid booster shots while millions worldwide lack first jab". France 24. Agence France-Presse. 18 August 2021. Archived from the original on 2 November 2021. Retrieved 21 August 2021.
- "France plans rollout of Covid vaccine booster shots – but only for the vulnerable". France 24. 4 August 2021. Archived from the original on 22 October 2021. Retrieved 16 August 2021.
gatesnotes.com
- Gates B (30 April 2020). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.
gavi.org
- "What are viral vector-based vaccines and how could they be used against COVID-19?". Gavi, the Vaccine Alliance (GAVI). 2020. Archived from the original on 11 November 2021. Retrieved 26 January 2021.
- Joi P (13 July 2021). "Could a universal coronavirus vaccine soon be a reality?". GAVI. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
ghostarchive.org
- Rasgon A (4 February 2021). "Israel's Vaccine Success Unleashes a Debate on Palestinian Inequities". The New York Times. Archived from the original on 28 December 2021. Retrieved 17 February 2021.
github.com
- "(OWID) vaccination maps". Our World in Data. Archived from the original on 21 December 2021. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. (5 March 2020). "Data FAQ". Our World in Data. Archived from the original on 10 March 2021.
globalnews.ca
- Dangerfield K (20 November 2020). "Pfizer files for emergency use of coronavirus vaccine in U.S. – what about in Canada?". Global News. Archived from the original on 25 January 2021. Retrieved 25 November 2020.
- Abedi M (23 March 2020). "Canada to spend $192M on developing COVID-19 vaccine". Global News. Archived from the original on 9 April 2020. Retrieved 24 March 2020.
gov.uk
- "Research and analysis — Coronavirus vaccine - weekly summary of Yellow Card reporting". Medicines and Healthcare products Regulatory Agency (MHRA). 1 April 2021. Archived from the original on 20 May 2021. Retrieved 3 April 2020.
- "Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Archived from the original on 15 March 2021. Retrieved 13 December 2020.
- "Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 3 December 2020. Archived from the original on 26 February 2021. Retrieved 19 December 2020.
- "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Archived from the original on 17 March 2021. Retrieved 2 December 2020.
gulfnews.com
- "UAE: Ministry of Health announces 86 per cent vaccine efficacy". Gulf News. Archived from the original on 24 December 2020. Retrieved 9 December 2020.
handle.net
hdl.handle.net
- Background document on the mRNA-1273 vaccine (Moderna) against COVID-19 (Report). World Health Organization (WHO). February 2021. hdl:10665/339218. WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1. Archived from the original on 13 June 2021. Retrieved 24 July 2021.
- Verbeke R, Lentacker I, De Smedt SC, Dewitte H (October 2019). "Three decades of messenger RNA vaccine development". Nano Today. 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. S2CID 202221207. Archived from the original on 9 October 2021. Retrieved 17 January 2021.
- Male V (January 2022). "Menstruation and covid-19 vaccination". BMJ. 376: o142. doi:10.1136/bmj.o142. hdl:10044/1/94577. PMID 35082132. S2CID 246287912.
- Basso C (October 2022). "Myocarditis". The New England Journal of Medicine. 387 (16): 1488–1500. doi:10.1056/NEJMra2114478. hdl:11577/3479721. PMID 36260793. S2CID 240234869.
harvard.edu
ui.adsabs.harvard.edu
- Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Van Noorden R (December 2021). "How COVID vaccines shaped 2021 in eight powerful charts". Nature. 600 (7890): 580–583. Bibcode:2021Natur.600..580M. doi:10.1038/d41586-021-03686-x. PMID 34916666. S2CID 245262732.
- Butler D (October 2012). "SARS veterans tackle coronavirus". Nature. 490 (7418): 20. Bibcode:2012Natur.490...20B. doi:10.1038/490020a. PMID 23038444.
- Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. (August 2021). "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses". Nature. 596 (7870): 109–113. Bibcode:2021Natur.596..109T. doi:10.1038/s41586-021-03738-2. PMC 8935394. PMID 34182569.
- Arbeitman CR, Rojas P, Ojeda-May P, Garcia ME (September 2021). "The SARS-CoV-2 spike protein is vulnerable to moderate electric fields". Nature Communications. 12 (1): 5407. arXiv:2103.12733. Bibcode:2021NatCo..12.5407A. doi:10.1038/s41467-021-25478-7. PMC 8437970. PMID 34518528.
- Krammer F (October 2020). "SARS-CoV-2 vaccines in development". Nature. 586 (7830): 516–527. Bibcode:2020Natur.586..516K. doi:10.1038/s41586-020-2798-3. PMID 32967006. S2CID 221887746.
- Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. (August 2020). "A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge". Nat Commun. 11 (1): 4081. Bibcode:2020NatCo..11.4081W. doi:10.1038/s41467-020-17972-1. PMC 7427994. PMID 32796842.
- Waltz E (September 2022). "China and India approve nasal COVID vaccines - are they a game changer?". Nature. 609 (7927): 450. Bibcode:2022Natur.609..450W. doi:10.1038/d41586-022-02851-0. PMID 36071228. S2CID 252121594.
- Thorp HH (March 2020). "Underpromise, overdeliver". Science. 367 (6485): 1405. Bibcode:2020Sci...367.1405T. doi:10.1126/science.abb8492. PMID 32205459. S2CID 214628067.
- Cohen J (June 2020). "Pandemic vaccines are about to face the real test". Science. 368 (6497): 1295–96. Bibcode:2020Sci...368.1295C. doi:10.1126/science.368.6497.1295. PMID 32554572. S2CID 219911109.
- Cohen J (May 2020). "U.S. 'Warp Speed' vaccine effort comes out of the shadows". Science. 368 (6492): 692–93. Bibcode:2020Sci...368..692C. doi:10.1126/science.368.6492.692. PMID 32409451.
- Altmann DM, Boyton RJ (March 2022). "COVID-19 vaccination: The road ahead". Science. 375 (6585): 1127–1132. Bibcode:2022Sci...375.1127A. doi:10.1126/science.abn1755. PMID 35271316. S2CID 247384207.
- "The WHO is right to call a temporary halt to COVID vaccine boosters". Nature. 596 (7872): 317. August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262.
hbr.org
- Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
- Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
ijidonline.com
- Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, et al. (January 2023). "Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children". International Journal of Infectious Diseases. 126: 164–173. doi:10.1016/j.ijid.2022.11.016. PMC 9673084. PMID 36403819. Retrieved 28 June 2024.
ina-registry.org
- PT. Bio Farma (August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
independent.co.uk
- "In a first, AstraZeneca admits its Covid vaccine can cause rare blood clots". The Independent. 30 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
- Lintern S (2 December 2020). "Pfizer given protection from legal action over coronavirus vaccine by UK government". The Independent. Archived from the original on 5 May 2021. Retrieved 8 May 2021.
isrctn.com
- "Phase I vaccine study of pEVAC-PS coronavirus vaccine". www.isrctn.com. Retrieved 30 August 2024.
ivi.int
- "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID‑19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Archived from the original on 24 September 2020. Retrieved 23 April 2020.
kron4.com
- "MLB offers free tickets for COVID-19 vaccinations". Kron4. 4 June 2021. Retrieved 4 October 2021.
krqe.com
- Burakovsky A (28 August 2021). "Russia's COVID-19 response slowed by population reluctant to take domestic vaccine". KRQE. Retrieved 20 September 2021.
latimes.com
- "Among the unvaccinated, Delta variant more than doubles risk of hospitalization". Los Angeles Times. 28 August 2021. Archived from the original on 8 November 2021.
medigenvac.com
- "MVC COVID-19 Vaccine Obtains Taiwan EUA Approval". Medigen Vaccine Biologics. Archived from the original on 27 November 2021. Retrieved 7 August 2021.
msf.org
- "MSF calls for no patents or profiteering on COVID-19 drugs and vaccines / No profiteering on COVID-19 drugs and vaccines, says MSF". Médecins Sans Frontières (MSF) International. Archived from the original on 26 November 2021. Retrieved 23 September 2021.
- "Governments must act fast on consensus supporting historic move to suspend monopolies during pandemic / COVID-19: Governments must build consensus around waiver". Médecins Sans Frontières (MSF) International. Archived from the original on 23 October 2021. Retrieved 23 September 2021.
msfindia.in
- "Countries must not let another opportunity slip by to advance the global waiver on overcoming COVID-19 medical-tool monopolies". Médecins Sans Frontières (MSF)/Doctors Without Borders. 13 September 2021. Archived from the original on 10 October 2021. Retrieved 23 September 2021.
msu.edu
users.math.msu.edu
- Wang R, Chen J, Wei GW (December 2021). "Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America" (PDF). The Journal of Physical Chemistry Letters. 12 (49): 11850–11857. doi:10.1021/acs.jpclett.1c03380. PMC 8672435. PMID 34873910. Archived (PDF) from the original on 18 December 2021. Retrieved 27 January 2022.
mysociety.org
- Taylor R (2 November 2021). "Sequences of Covid-19 vaccines released via WhatDoTheyKnow". mySociety. Archived from the original on 5 November 2021. Retrieved 2 November 2021.
nationalgeographic.com
- Kramer J (18 August 2021). "The U.S. plans to authorize boosters—but many already got a third dose". National Geographic. Archived from the original on 10 October 2021. Retrieved 21 August 2021.
nationalpost.com
- Blackwell T (20 April 2020). "COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work". National Post. Archived from the original on 24 April 2020. Retrieved 3 May 2020.
nbcnews.com
- Bush E (15 December 2021). "Fauci pushes for universal coronavirus vaccine". NBC News. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
ndtv.com
- Achom D (28 December 2021). "India Clears 2 New Vaccines And Merck's Covid Pill: 10 Points". NDTV.com. Archived from the original on 28 December 2021. Retrieved 19 January 2022.
newatlas.com
- Haridy R (7 July 2022). "Another universal coronavirus vaccine readies for human trials". New Atlas. Archived from the original on 11 July 2022. Retrieved 11 July 2022.
newrepublic.com
- Schreiber M, Chayka K, Chayka K, Beyerstein L, Beyerstein L, Wilson J, et al. (1 July 2021). "The Delta Covid Variant's Urgent Message for America". The New Republic. ISSN 0028-6583. Archived from the original on 28 August 2021. Retrieved 28 October 2021.
news-medical.net
- "Study findings suggest spread of Omicron can be ascribed to immune evasiveness rather than an increase in transmissibility". News-Medical.net. 5 January 2022. Archived from the original on 21 January 2022. Retrieved 17 January 2022.
nhc.gov.cn
- "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.
nhs.uk
- "Pregnancy, breastfeeding, fertility and coronavirus (COVID-19) vaccination". NHS. 5 October 2022. Archived from the original on 15 October 2022. Retrieved 15 October 2022.
- "SARS (severe acute respiratory syndrome)". National Health Service. 5 March 2020. Archived from the original on 9 March 2020. Retrieved 31 January 2020.
- "Coronavirus (COVID-19) booster vaccine". NHS. Government Digital Service. 17 September 2021. Retrieved 11 December 2021.
nih.gov
pubmed.ncbi.nlm.nih.gov
- Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. PMC 7749790. PMID 33341119.
- Subbarao K (July 2021). "The success of SARS-CoV-2 vaccines and challenges ahead". Cell Host & Microbe. 29 (7): 1111–1123. doi:10.1016/j.chom.2021.06.016. PMC 8279572. PMID 34265245.
- Dodaran MS, Banihashemi SR, Es-haghi A, Mehrabadi MH, Nofeli M, Mokarram AR, et al. (16 February 2023). "Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial". Vaccines. 11 (2): 455. doi:10.3390/vaccines11020455. PMC 9961243. PMID 36851334.
- Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, et al. (January 2023). "Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children". International Journal of Infectious Diseases. 126: 164–173. doi:10.1016/j.ijid.2022.11.016. PMC 9673084. PMID 36403819. Retrieved 28 June 2024.
- Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Van Noorden R (December 2021). "How COVID vaccines shaped 2021 in eight powerful charts". Nature. 600 (7890): 580–583. Bibcode:2021Natur.600..580M. doi:10.1038/d41586-021-03686-x. PMID 34916666. S2CID 245262732.
- Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (June 2022). "Global impact of the first year of COVID-19 vaccination: a mathematical modelling study". The Lancet Infectious Diseases. 22 (9): 1293–1302. doi:10.1016/s1473-3099(22)00320-6. PMC 9225255. PMID 35753318.
- Wang H, Xu R, Qu S, Schwartz M, Adams A, Chen X (October 2021). "Health inequities in COVID-19 vaccination among the elderly: Case of Connecticut". Journal of Infection and Public Health. 14 (10): 1563–1565. doi:10.1016/j.jiph.2021.07.013. PMC 8491089. PMID 34326008. S2CID 236515442.
- Mullard A (November 2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811.
- So AD, Woo J (December 2020). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". BMJ. 371: m4750. doi:10.1136/bmj.m4750. PMC 7735431. PMID 33323376.
- Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. ISSN 0066-4219. PMID 34637324. S2CID 238747462.
- Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
- Cavanagh D (December 2003). "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus". Avian Pathology. 32 (6): 567–582. doi:10.1080/03079450310001621198. PMC 7154303. PMID 14676007.
- Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, et al. (December 2003). "Effects of a SARS-associated coronavirus vaccine in monkeys". Lancet. 362 (9399): 1895–1896. doi:10.1016/S0140-6736(03)14962-8. PMC 7112457. PMID 14667748.
- Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, et al. (October 2014). "Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice". Vaccine. 32 (45): 5975–5982. doi:10.1016/j.vaccine.2014.08.058. PMC 7115510. PMID 25192975.
- Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, et al. (February 2005). "Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice". The Journal of Infectious Diseases. 191 (4): 507–514. doi:10.1086/427242. PMC 7110081. PMID 15655773.
- Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, et al. (September 2005). "Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins". Journal of Virological Methods. 128 (1–2): 21–28. doi:10.1016/j.jviromet.2005.03.021. PMC 7112802. PMID 15885812.
- Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, et al. (March 2006). "Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters". The Journal of Infectious Diseases. 193 (5): 685–692. doi:10.1086/500143. PMC 7109703. PMID 16453264.
- Jiang S, Lu L, Du L (January 2013). "Development of SARS vaccines and therapeutics is still needed". Future Virology. 8 (1): 1–2. doi:10.2217/fvl.12.126. PMC 7079997. PMID 32201503.
- Shehata MM, Gomaa MR, Ali MA, Kayali G (June 2016). "Middle East respiratory syndrome coronavirus: a comprehensive review". Frontiers of Medicine. 10 (2): 120–136. doi:10.1007/s11684-016-0430-6. PMC 7089261. PMID 26791756.
- Butler D (October 2012). "SARS veterans tackle coronavirus". Nature. 490 (7418): 20. Bibcode:2012Natur.490...20B. doi:10.1038/490020a. PMID 23038444.
- Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. (September 2019). "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial". The Lancet. Infectious Diseases. 19 (9): 1013–1022. doi:10.1016/S1473-3099(19)30266-X. PMC 7185789. PMID 31351922.
- Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS (2019). "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus". Frontiers in Microbiology. 10: 1781. doi:10.3389/fmicb.2019.01781. PMC 6688523. PMID 31428074.
- Sharma O, Sultan AA, Ding H, Triggle CR (14 October 2020). "A Review of the Progress and Challenges of Developing a Vaccine for COVID-19". Frontiers in Immunology. 11: 585354. doi:10.3389/fimmu.2020.585354. PMC 7591699. PMID 33163000.
- Bok K, Sitar S, Graham BS, Mascola JR (August 2021). "Accelerated COVID-19 vaccine development: milestones, lessons, and prospects". Immunity. 54 (8): 1636–1651. doi:10.1016/j.immuni.2021.07.017. PMC 8328682. PMID 34348117.
- Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. (August 2021). "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses". Nature. 596 (7870): 109–113. Bibcode:2021Natur.596..109T. doi:10.1038/s41586-021-03738-2. PMC 8935394. PMID 34182569.
- Flanagan KL, Best E, Crawford NW, Giles M, Koirala A, Macartney K, et al. (2020). "Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines". Frontiers in Immunology. 11: 579250. doi:10.3389/fimmu.2020.579250. PMC 7566192. PMID 33123165.
- Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
- Arbeitman CR, Rojas P, Ojeda-May P, Garcia ME (September 2021). "The SARS-CoV-2 spike protein is vulnerable to moderate electric fields". Nature Communications. 12 (1): 5407. arXiv:2103.12733. Bibcode:2021NatCo..12.5407A. doi:10.1038/s41467-021-25478-7. PMC 8437970. PMID 34518528.
- Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. (June 2020). "Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals". Cell. 181 (7): 1489–1501.e15. doi:10.1016/j.cell.2020.05.015. PMC 7237901. PMID 32473127.
- Dutta NK, Mazumdar K, Gordy JT (June 2020). Dutch RE (ed.). "The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development". Journal of Virology. 94 (13). doi:10.1128/JVI.00647-20. PMC 7307180. PMID 32546606.
- Nikolaidis M, Markoulatos P, Van de Peer Y, Oliver SG, Amoutzias GD (October 2021). Hepp C (ed.). "The neighborhood of the Spike gene is a hotspot for modular intertypic homologous and non-homologous recombination in Coronavirus genomes". Molecular Biology and Evolution. 39: msab292. doi:10.1093/molbev/msab292. PMC 8549283. PMID 34638137.
- Amoutzias GD, Nikolaidis M, Tryfonopoulou E, Chlichlia K, Markoulatos P, Oliver SG (January 2022). "The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2". Viruses. 14 (1): 78. doi:10.3390/v14010078. PMC 8778387. PMID 35062282.
- Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–06. doi:10.1038/d41573-020-00073-5. PMID 32273591.
- Diamond MS, Pierson TC (May 2020). "The Challenges of Vaccine Development against a New Virus during a Pandemic". Cell Host & Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
- Krammer F (October 2020). "SARS-CoV-2 vaccines in development". Nature. 586 (7830): 516–527. Bibcode:2020Natur.586..516K. doi:10.1038/s41586-020-2798-3. PMID 32967006. S2CID 221887746.
- Park KS, Sun X, Aikins ME, Moon JJ (February 2021). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews. 169: 137–151. doi:10.1016/j.addr.2020.12.008. ISSN 0169-409X. PMC 7744276. PMID 33340620.
- Kowalski PS, Rudra A, Miao L, Anderson DG (April 2019). "Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery". Molecular Therapy. 27 (4): 710–728. doi:10.1016/j.ymthe.2019.02.012. PMC 6453548. PMID 30846391.
- Moghimi SM (March 2021). "Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines". Molecular Therapy. 29 (3): 898–900. doi:10.1016/j.ymthe.2021.01.030. PMC 7862013. PMID 33571463.
- Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. (August 2020). "A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge". Nat Commun. 11 (1): 4081. Bibcode:2020NatCo..11.4081W. doi:10.1038/s41467-020-17972-1. PMC 7427994. PMID 32796842.
- Petrovsky N, Aguilar JC (October 2004). "Vaccine adjuvants: current state and future trends". Immunology and Cell Biology. 82 (5): 488–496. doi:10.1111/j.0818-9641.2004.01272.x. PMID 15479434. S2CID 154670.
- Mudgal R, Nehul S, Tomar S (December 2020). "Prospects for mucosal vaccine: shutting the door on SARS-CoV-2". Human Vaccines & Immunotherapeutics. 16 (12): 2921–2931. doi:10.1080/21645515.2020.1805992. PMC 7544966. PMID 32931361.
- Waltz E (September 2022). "China and India approve nasal COVID vaccines - are they a game changer?". Nature. 609 (7927): 450. Bibcode:2022Natur.609..450W. doi:10.1038/d41586-022-02851-0. PMID 36071228. S2CID 252121594.
- Dhama K, Dhawan M, Tiwari R, Emran TB, Mitra S, Rabaan AA, et al. (November 2022). "COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges". Human Vaccines & Immunotherapeutics. 18 (5): 2045853. doi:10.1080/21645515.2022.2045853. PMC 8935456. PMID 35258416.
- Nistor GI, Dillman RO, Robles RM, Langford JL, Poole AJ, Sofro MA, et al. (August 2022). "A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses". Human Vaccines & Immunotherapeutics. 18 (6): 2100189. doi:10.1080/21645515.2022.2100189. PMC 9746383. PMID 36018753.
- Ober Shepherd BL, Scott PT, Hutter JN, Lee C, McCauley MD, Guzman I, et al. (EID-030 Study Group) (June 2024). "SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial". The Lancet. Microbe. 5 (6): e581–e593. doi:10.1016/S2666-5247(23)00410-X. PMC 11192176. PMID 38761816.
- Tregoning JS, Russell RF, Kinnear E (March 2018). "Adjuvanted influenza vaccines". Human Vaccines & Immunotherapeutics. 14 (3): 550–564. doi:10.1080/21645515.2017.1415684. PMC 5861793. PMID 29232151.
- Wang J, Peng Y, Xu H, Cui Z, Williams RO (August 2020). "The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation". AAPS PharmSciTech. 21 (6): 225. doi:10.1208/s12249-020-01744-7. PMC 7405756. PMID 32761294.
- Simpson S, Kaufmann MC, Glozman V, Chakrabarti A (May 2020). "Disease X: accelerating the development of medical countermeasures for the next pandemic". The Lancet. Infectious Diseases. 20 (5): e108–15. doi:10.1016/S1473-3099(20)30123-7. PMC 7158580. PMID 32197097.
- Zabaleta N, Dai W, Bhatt U, Hérate C, Maisonnasse P, Chichester JA, et al. (August 2021). "An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates". Cell Host & Microbe. 29 (9): 1437–1453.e8. doi:10.1016/j.chom.2021.08.002. PMC 8346325. PMID 34428428. S2CID 231676030.
- Thorp HH (March 2020). "Underpromise, overdeliver". Science. 367 (6485): 1405. Bibcode:2020Sci...367.1405T. doi:10.1126/science.abb8492. PMID 32205459. S2CID 214628067.
- Cohen J (June 2020). "Pandemic vaccines are about to face the real test". Science. 368 (6497): 1295–96. Bibcode:2020Sci...368.1295C. doi:10.1126/science.368.6497.1295. PMID 32554572. S2CID 219911109.
- Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J (August 2013). "Vaccine hesitancy: an overview". Human Vaccines & Immunotherapeutics. 9 (8): 1763–73. doi:10.4161/hv.24657. PMC 3906279. PMID 23584253.
- Cohen J (May 2020). "U.S. 'Warp Speed' vaccine effort comes out of the shadows". Science. 368 (6492): 692–93. Bibcode:2020Sci...368..692C. doi:10.1126/science.368.6492.692. PMID 32409451.
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (June 2021). "Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination". The New England Journal of Medicine. 384 (22): 2092–101. doi:10.1056/NEJMoa2104840. PMC 8095372. PMID 33835769.
- Cines DB, Bussel JB (June 2021). "SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia". The New England Journal of Medicine. 384 (23): 2254–2256. doi:10.1056/NEJMe2106315. PMC 8063912. PMID 33861524.
- Liu Y, Shao Z, Wang H (December 2021). "SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia". Thrombosis Research. 209: 75–79. doi:10.1016/j.thromres.2021.12.002. PMC 8647389. PMID 34894531.
- Klok FA, Pai M, Huisman MV, Makris M (November 2021). "Vaccine-induced immune thrombotic thrombocytopenia". The Lancet. Haematology. 9 (1): e73–e80. doi:10.1016/S2352-3026(21)00306-9. PMC 8585488. PMID 34774202.
Although initially several terms were used to describe the syndrome … the term that has gained widespread use is vaccine-induced immune thrombotic thrombocytopenia (VITT). Thrombosis with thrombocytopenia syndrome has also been used, but it is a more general term that can be caused by other conditions
- Warkentin TE, Pai M (October 2021). "Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res 2021 in press". Thrombosis Research. 207: 158–160. doi:10.1016/j.thromres.2021.10.007. PMID 34757250. S2CID 239574011.
We believe the name "VITT" works well … the term clearly denotes the key features of the disorder … provides a useful mnemonic for disease recognition in the usual sequence of events … need not mandate that thrombosis be present … "TTS" … has limited clinical utility, since many conditions … present with the duad of thrombosis and thrombocytopenia
- Long B, Bridwell R, Gottlieb M (November 2021). "Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines". The American Journal of Emergency Medicine. 49: 58–61. doi:10.1016/j.ajem.2021.05.054. PMC 8143907. PMID 34062319.
- Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. (May 2020). "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. PMID 32273591.
- Gates B (February 2020). "Responding to Covid-19: A once-in-a-century pandemic?". The New England Journal of Medicine. 382 (18): 1677–79. doi:10.1056/nejmp2003762. PMID 32109012.
- Fauci AS, Lane HC, Redfield RR (March 2020). "Covid-19: Navigating the uncharted". The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
- Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–668. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
- Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). "Ensuring global access to COVID‑19 vaccines". Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778.
CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
- Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
- Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
- Yang ZR, Jiang YW, Li FX, Liu D, Lin TF, Zhao ZY, et al. (April 2023). "Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials". The Lancet. Microbe. 4 (4): e236–e246. doi:10.1016/S2666-5247(22)00390-1. PMC 9974155. PMID 36868258.
- Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. (September 2021). "Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (37): 1284–1290. doi:10.15585/mmwr.mm7037e1. PMC 8445374. PMID 34529637.
- Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–1169. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521.
- Lee AR, Wong SY, Chai LY, Lee SC, Lee MX, Muthiah MD, et al. (March 2022). "Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis". BMJ. 376: e068632. doi:10.1136/bmj-2021-068632. PMC 8889026. PMID 35236664.
- Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL (August 2021). "Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies". Cancer Cell. 39 (8): 1031–1033. doi:10.1016/j.ccell.2021.07.012. PMC 8295014. PMID 34331856.
- Stein C, Nassereldine H, Sorensen RJ, Amlag JO, Bisignano C, Byrne S, et al. (February 2023). "Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis". The Lancet. 401 (10379): 833–842. doi:10.1016/S0140-6736(22)02465-5. ISSN 0140-6736. PMC 9998097. PMID 36930674.
- Payne AB (2024). "Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (1): 16–23. doi:10.15585/mmwr.mm7301a4. ISSN 0149-2195. PMC 10794061. PMID 38206877. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
- Català M, Mercadé-Besora N, Kolde R, Trinh NT, Roel E, Burn E, et al. (March 2024). "The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia". The Lancet. Respiratory Medicine. 12 (3): 225–236. doi:10.1016/s2213-2600(23)00414-9. PMID 38219763.
- Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. (December 2021). "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months". The New England Journal of Medicine. 385 (24): e84. doi:10.1056/NEJMoa2114583. PMC 8522797. PMID 34614326.
- Wang R, Chen J, Wei GW (December 2021). "Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America" (PDF). The Journal of Physical Chemistry Letters. 12 (49): 11850–11857. doi:10.1021/acs.jpclett.1c03380. PMC 8672435. PMID 34873910. Archived (PDF) from the original on 18 December 2021. Retrieved 27 January 2022.
- Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. (February 2022). "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies". Nature. 602 (7898): 657–663. doi:10.1038/d41586-021-03796-6. PMC 8866119. PMID 35016194. S2CID 245455422.
- Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. (February 2022). "Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2". Nature. 602 (7898): 676–681. doi:10.1038/d41586-021-03826-3. PMID 35016198. S2CID 245462866.
- Mohsin M, Mahmud S (May 2022). "Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity". Medicine. 101 (19): e29165. doi:10.1097/MD.0000000000029165. PMC 9276130. PMID 35583528. S2CID 248858919.
- Shin DH, Smith DM, Choi JY (2022). "SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask". Yonsei Medical Journal. 63 (11): 977–983. doi:10.3349/ymj.2022.0383. PMC 9629902. PMID 36303305.
- Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. (February 2022). "Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study". The Lancet. Infectious Diseases. 22 (2): 183–195. doi:10.1016/S1473-3099(21)00648-4. PMC 8554486. PMID 34756186.
- Callaway E (October 2021). "Mix-and-match COVID vaccines ace the effectiveness test". Nature. doi:10.1038/d41586-021-02853-4. PMID 34675430. S2CID 239455075.
- Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N (April 2022). "COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts". Journal of Medical Virology. 94 (4): 1294–1299. doi:10.1002/jmv.27463. PMC 8661746. PMID 34796525.
- Al-Haideri MT, Mannani R, Kaboli R, Gharebakhshi F, Darvishzadehdeldari S, Tahmasebi S, et al. (August 2023). "The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence". Transplant Immunology. 79: 101858. doi:10.1016/j.trim.2023.101858. PMC 10205646. PMID 37236514.
- Wroński J, Ciechomska M, Kuca-Warnawin E (September 2023). "Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 165: 115254. doi:10.1016/j.biopha.2023.115254. PMID 37542854.
- Imran M, Ali S, Ibrahim AA, Amjad A, Tanveer A, Khalil S, et al. (July 2024). "Effect of methotrexate hold on COVID-19 vaccine response in the patients with autoimmune inflammatory disorders: a systematic review and meta-analysis". Clinical Rheumatology. 43 (7): 2203–2214. doi:10.1007/s10067-024-07013-3. PMID 38802670.
- Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Francis A, et al. (February 2024). "Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial". The Lancet. Rheumatology. 6 (2): e92–e104. doi:10.1016/S2665-9913(23)00298-9. PMID 38267107.
- Kouhpayeh H, Ansari H (August 2022). "Adverse events following COVID-19 vaccination: A systematic review and meta-analysis". International Immunopharmacology. 109: 108906. doi:10.1016/j.intimp.2022.108906. PMC 9148928. PMID 35671640.
- Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, et al. (December 2022). "Efficacy and safety of COVID-19 vaccines". The Cochrane Database of Systematic Reviews. 12 (12): CD015477. doi:10.1002/14651858.CD015477. PMC 9726273. PMID 36473651.
- Haas JW, Bender FL, Ballou S, Kelley JM, Wilhelm M, Miller FG, et al. (January 2022). "Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis". JAMA Network Open. 5 (1): e2143955. doi:10.1001/jamanetworkopen.2021.43955. PMC 8767431. PMID 35040967.
- Polania Gutierrez JJ, Munakomi S (January 2020). "Intramuscular Injection". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32310581. Archived from the original on 8 December 2020. Retrieved 24 July 2021.
- Huang Z, Su Y, Zhang T, Xia N (February 2022). "A review of the safety and efficacy of current COVID-19 vaccines". Frontiers of Medicine. 16 (1): 39–55. doi:10.1007/s11684-021-0893-y. PMC 8815389. PMID 35122210.
- Tu W, Gierada DS, Joe BN (May 2021). "COVID-19 Vaccination-Related Lymphadenopathy: What To Be Aware Of". Radiology. Imaging Cancer. 3 (3): e210038. doi:10.1148/rycan.2021210038. PMC 8049171. PMID 33874733.
- Male V (January 2022). "Menstruation and covid-19 vaccination". BMJ. 376: o142. doi:10.1136/bmj.o142. hdl:10044/1/94577. PMID 35082132. S2CID 246287912.
- Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. (October 2021). "Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military". JAMA Cardiology. 6 (10): 1202–06. doi:10.1001/jamacardio.2021.2833. PMC 8243257. PMID 34185045.
- Frontera JA, Tamborska AA, Doheim MF, Garcia-Azorin D, Gezegen H, Guekht A, et al. (March 2022). "Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS". Annals of Neurology. 91 (6): 756–771. doi:10.1002/ana.26339. PMC 9082459. PMID 35233819.
- Altmann DM, Boyton RJ (March 2022). "COVID-19 vaccination: The road ahead". Science. 375 (6585): 1127–1132. Bibcode:2022Sci...375.1127A. doi:10.1126/science.abn1755. PMID 35271316. S2CID 247384207.
- Basso C (October 2022). "Myocarditis". The New England Journal of Medicine. 387 (16): 1488–1500. doi:10.1056/NEJMra2114478. hdl:11577/3479721. PMID 36260793. S2CID 240234869.
- Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. (December 2021). "Myocarditis after Covid-19 Vaccination in a Large Health Care Organization". The New England Journal of Medicine. 385 (23): 2132–2139. doi:10.1056/NEJMoa2110737. PMC 8531986. PMID 34614329. S2CID 238421512.
- Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. (September 2022). "Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex". Circulation. 146 (10): 743–754. doi:10.1161/CIRCULATIONAHA.122.059970. PMC 9439633. PMID 35993236.
- Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. (April 2022). "New-onset autoimmune phenomena post-COVID-19 vaccination". Immunology. 165 (4): 386–401. doi:10.1111/imm.13443. PMID 34957554. S2CID 245522029.
- Jafari Z, Kolb BE, Mohajerani MH (March 2022). "Hearing Loss, Tinnitus, and Dizziness in COVID-19: A Systematic Review and Meta-Analysis". The Canadian Journal of Neurological Sciences. 49 (2): 184–195. doi:10.1017/cjn.2021.63. PMC 8267343. PMID 33843530.
- Slomski A (May 2022). "Studies Examine Risk of Hearing Loss After COVID-19 Vaccination". JAMA. 327 (17): 1641. doi:10.1001/jama.2022.6719. PMID 35503358. S2CID 248502943.
- Dorney I, Bobak L, Otteson T, Kaelber DC (September 2022). "Prevalence of New-Onset Tinnitus after COVID-19 Vaccination with Comparison to Other Vaccinations". The Laryngoscope. 133 (7): 1722–1725. doi:10.1002/lary.30395. PMC 9539087. PMID 36098476.
- Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. (2021). "A global database of COVID-19 vaccinations". Nature Human Behaviour. 5 (7): 947–953. doi:10.1038/s41562-021-01122-8. PMID 33972767.
- Gates B (April 2020). "Responding to Covid-19 - A Once-in-a-Century Pandemic?". The New England Journal of Medicine. 382 (18): 1677–1679. doi:10.1056/nejmp2003762. PMID 32109012.
- The Lancet Infectious Diseases Editors (September 2021). "COVID-19 vaccine equity and booster doses". The Lancet Infectious Diseases. 21 (9): 1193. doi:10.1016/S1473-3099(21)00486-2. PMC 8360703. PMID 34391506.
- Mahase E (July 2021). "Covid-19: Countries dump vaccines as demand slumps and sharing proves difficult". BMJ. 374: n1893. doi:10.1136/bmj.n1893. PMID 34315725. S2CID 236457553.
- "The WHO is right to call a temporary halt to COVID vaccine boosters". Nature. 596 (7872): 317. August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262.
- Baraniuk C (February 2021). "Covid-19: How the UK vaccine rollout delivered success, so far". BMJ. 372: n421. doi:10.1136/bmj.n421. PMID 33602672. S2CID 231946710.
- Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR Morb Mortal Wkly Rep. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 9 June 2021.
ncbi.nlm.nih.gov
- Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. PMC 7749790. PMID 33341119.
- Subbarao K (July 2021). "The success of SARS-CoV-2 vaccines and challenges ahead". Cell Host & Microbe. 29 (7): 1111–1123. doi:10.1016/j.chom.2021.06.016. PMC 8279572. PMID 34265245.
- Dodaran MS, Banihashemi SR, Es-haghi A, Mehrabadi MH, Nofeli M, Mokarram AR, et al. (16 February 2023). "Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial". Vaccines. 11 (2): 455. doi:10.3390/vaccines11020455. PMC 9961243. PMID 36851334.
- Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, et al. (January 2023). "Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children". International Journal of Infectious Diseases. 126: 164–173. doi:10.1016/j.ijid.2022.11.016. PMC 9673084. PMID 36403819. Retrieved 28 June 2024.
- Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC (June 2022). "Global impact of the first year of COVID-19 vaccination: a mathematical modelling study". The Lancet Infectious Diseases. 22 (9): 1293–1302. doi:10.1016/s1473-3099(22)00320-6. PMC 9225255. PMID 35753318.
- Wang H, Xu R, Qu S, Schwartz M, Adams A, Chen X (October 2021). "Health inequities in COVID-19 vaccination among the elderly: Case of Connecticut". Journal of Infection and Public Health. 14 (10): 1563–1565. doi:10.1016/j.jiph.2021.07.013. PMC 8491089. PMID 34326008. S2CID 236515442.
- So AD, Woo J (December 2020). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". BMJ. 371: m4750. doi:10.1136/bmj.m4750. PMC 7735431. PMID 33323376.
- Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
- Cavanagh D (December 2003). "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus". Avian Pathology. 32 (6): 567–582. doi:10.1080/03079450310001621198. PMC 7154303. PMID 14676007.
- Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, et al. (December 2003). "Effects of a SARS-associated coronavirus vaccine in monkeys". Lancet. 362 (9399): 1895–1896. doi:10.1016/S0140-6736(03)14962-8. PMC 7112457. PMID 14667748.
- Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, et al. (October 2014). "Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice". Vaccine. 32 (45): 5975–5982. doi:10.1016/j.vaccine.2014.08.058. PMC 7115510. PMID 25192975.
- Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, et al. (February 2005). "Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice". The Journal of Infectious Diseases. 191 (4): 507–514. doi:10.1086/427242. PMC 7110081. PMID 15655773.
- Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, et al. (September 2005). "Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins". Journal of Virological Methods. 128 (1–2): 21–28. doi:10.1016/j.jviromet.2005.03.021. PMC 7112802. PMID 15885812.
- Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, et al. (March 2006). "Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters". The Journal of Infectious Diseases. 193 (5): 685–692. doi:10.1086/500143. PMC 7109703. PMID 16453264.
- Jiang S, Lu L, Du L (January 2013). "Development of SARS vaccines and therapeutics is still needed". Future Virology. 8 (1): 1–2. doi:10.2217/fvl.12.126. PMC 7079997. PMID 32201503.
- Shehata MM, Gomaa MR, Ali MA, Kayali G (June 2016). "Middle East respiratory syndrome coronavirus: a comprehensive review". Frontiers of Medicine. 10 (2): 120–136. doi:10.1007/s11684-016-0430-6. PMC 7089261. PMID 26791756.
- Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. (September 2019). "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial". The Lancet. Infectious Diseases. 19 (9): 1013–1022. doi:10.1016/S1473-3099(19)30266-X. PMC 7185789. PMID 31351922.
- Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS (2019). "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus". Frontiers in Microbiology. 10: 1781. doi:10.3389/fmicb.2019.01781. PMC 6688523. PMID 31428074.
- Sharma O, Sultan AA, Ding H, Triggle CR (14 October 2020). "A Review of the Progress and Challenges of Developing a Vaccine for COVID-19". Frontiers in Immunology. 11: 585354. doi:10.3389/fimmu.2020.585354. PMC 7591699. PMID 33163000.
- Bok K, Sitar S, Graham BS, Mascola JR (August 2021). "Accelerated COVID-19 vaccine development: milestones, lessons, and prospects". Immunity. 54 (8): 1636–1651. doi:10.1016/j.immuni.2021.07.017. PMC 8328682. PMID 34348117.
- Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. (August 2021). "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses". Nature. 596 (7870): 109–113. Bibcode:2021Natur.596..109T. doi:10.1038/s41586-021-03738-2. PMC 8935394. PMID 34182569.
- Flanagan KL, Best E, Crawford NW, Giles M, Koirala A, Macartney K, et al. (2020). "Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines". Frontiers in Immunology. 11: 579250. doi:10.3389/fimmu.2020.579250. PMC 7566192. PMID 33123165.
- Arbeitman CR, Rojas P, Ojeda-May P, Garcia ME (September 2021). "The SARS-CoV-2 spike protein is vulnerable to moderate electric fields". Nature Communications. 12 (1): 5407. arXiv:2103.12733. Bibcode:2021NatCo..12.5407A. doi:10.1038/s41467-021-25478-7. PMC 8437970. PMID 34518528.
- Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. (June 2020). "Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals". Cell. 181 (7): 1489–1501.e15. doi:10.1016/j.cell.2020.05.015. PMC 7237901. PMID 32473127.
- Dutta NK, Mazumdar K, Gordy JT (June 2020). Dutch RE (ed.). "The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development". Journal of Virology. 94 (13). doi:10.1128/JVI.00647-20. PMC 7307180. PMID 32546606.
- Nikolaidis M, Markoulatos P, Van de Peer Y, Oliver SG, Amoutzias GD (October 2021). Hepp C (ed.). "The neighborhood of the Spike gene is a hotspot for modular intertypic homologous and non-homologous recombination in Coronavirus genomes". Molecular Biology and Evolution. 39: msab292. doi:10.1093/molbev/msab292. PMC 8549283. PMID 34638137.
- Amoutzias GD, Nikolaidis M, Tryfonopoulou E, Chlichlia K, Markoulatos P, Oliver SG (January 2022). "The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2". Viruses. 14 (1): 78. doi:10.3390/v14010078. PMC 8778387. PMID 35062282.
- Diamond MS, Pierson TC (May 2020). "The Challenges of Vaccine Development against a New Virus during a Pandemic". Cell Host & Microbe. 27 (5): 699–703. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
- Park KS, Sun X, Aikins ME, Moon JJ (February 2021). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews. 169: 137–151. doi:10.1016/j.addr.2020.12.008. ISSN 0169-409X. PMC 7744276. PMID 33340620.
- Kowalski PS, Rudra A, Miao L, Anderson DG (April 2019). "Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery". Molecular Therapy. 27 (4): 710–728. doi:10.1016/j.ymthe.2019.02.012. PMC 6453548. PMID 30846391.
- Moghimi SM (March 2021). "Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines". Molecular Therapy. 29 (3): 898–900. doi:10.1016/j.ymthe.2021.01.030. PMC 7862013. PMID 33571463.
- Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. (August 2020). "A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge". Nat Commun. 11 (1): 4081. Bibcode:2020NatCo..11.4081W. doi:10.1038/s41467-020-17972-1. PMC 7427994. PMID 32796842.
- Mudgal R, Nehul S, Tomar S (December 2020). "Prospects for mucosal vaccine: shutting the door on SARS-CoV-2". Human Vaccines & Immunotherapeutics. 16 (12): 2921–2931. doi:10.1080/21645515.2020.1805992. PMC 7544966. PMID 32931361.
- Rhee JH (2020). "Current and New Approaches for Mucosal Vaccine Delivery". Mucosal Vaccines. Elsevier. pp. 325–356. doi:10.1016/b978-0-12-811924-2.00019-5. ISBN 9780128119242. PMC 7149853.
- Dhama K, Dhawan M, Tiwari R, Emran TB, Mitra S, Rabaan AA, et al. (November 2022). "COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges". Human Vaccines & Immunotherapeutics. 18 (5): 2045853. doi:10.1080/21645515.2022.2045853. PMC 8935456. PMID 35258416.
- Nistor GI, Dillman RO, Robles RM, Langford JL, Poole AJ, Sofro MA, et al. (August 2022). "A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses". Human Vaccines & Immunotherapeutics. 18 (6): 2100189. doi:10.1080/21645515.2022.2100189. PMC 9746383. PMID 36018753.
- Tregoning JS, Russell RF, Kinnear E (March 2018). "Adjuvanted influenza vaccines". Human Vaccines & Immunotherapeutics. 14 (3): 550–564. doi:10.1080/21645515.2017.1415684. PMC 5861793. PMID 29232151.
- Wang J, Peng Y, Xu H, Cui Z, Williams RO (August 2020). "The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation". AAPS PharmSciTech. 21 (6): 225. doi:10.1208/s12249-020-01744-7. PMC 7405756. PMID 32761294.
- Simpson S, Kaufmann MC, Glozman V, Chakrabarti A (May 2020). "Disease X: accelerating the development of medical countermeasures for the next pandemic". The Lancet. Infectious Diseases. 20 (5): e108–15. doi:10.1016/S1473-3099(20)30123-7. PMC 7158580. PMID 32197097.
- Zabaleta N, Dai W, Bhatt U, Hérate C, Maisonnasse P, Chichester JA, et al. (August 2021). "An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates". Cell Host & Microbe. 29 (9): 1437–1453.e8. doi:10.1016/j.chom.2021.08.002. PMC 8346325. PMID 34428428. S2CID 231676030.
- Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J (August 2013). "Vaccine hesitancy: an overview". Human Vaccines & Immunotherapeutics. 9 (8): 1763–73. doi:10.4161/hv.24657. PMC 3906279. PMID 23584253.
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (June 2021). "Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination". The New England Journal of Medicine. 384 (22): 2092–101. doi:10.1056/NEJMoa2104840. PMC 8095372. PMID 33835769.
- Cines DB, Bussel JB (June 2021). "SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia". The New England Journal of Medicine. 384 (23): 2254–2256. doi:10.1056/NEJMe2106315. PMC 8063912. PMID 33861524.
- Liu Y, Shao Z, Wang H (December 2021). "SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia". Thrombosis Research. 209: 75–79. doi:10.1016/j.thromres.2021.12.002. PMC 8647389. PMID 34894531.
- Klok FA, Pai M, Huisman MV, Makris M (November 2021). "Vaccine-induced immune thrombotic thrombocytopenia". The Lancet. Haematology. 9 (1): e73–e80. doi:10.1016/S2352-3026(21)00306-9. PMC 8585488. PMID 34774202.
Although initially several terms were used to describe the syndrome … the term that has gained widespread use is vaccine-induced immune thrombotic thrombocytopenia (VITT). Thrombosis with thrombocytopenia syndrome has also been used, but it is a more general term that can be caused by other conditions
- Long B, Bridwell R, Gottlieb M (November 2021). "Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines". The American Journal of Emergency Medicine. 49: 58–61. doi:10.1016/j.ajem.2021.05.054. PMC 8143907. PMID 34062319.
- Fauci AS, Lane HC, Redfield RR (March 2020). "Covid-19: Navigating the uncharted". The New England Journal of Medicine. 382 (13): 1268–69. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
- Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). "Ensuring global access to COVID‑19 vaccines". Lancet. 395 (10234): 1405–06. doi:10.1016/S0140-6736(20)30763-7. PMC 7271264. PMID 32243778.
CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
- Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
- Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). "Equitable access to COVID-19 vaccines makes a life-saving difference to all countries". Nature Human Behaviour. 6 (2): 207–216. doi:10.1038/s41562-022-01289-8. PMC 8873023. PMID 35102361.
- Yang ZR, Jiang YW, Li FX, Liu D, Lin TF, Zhao ZY, et al. (April 2023). "Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials". The Lancet. Microbe. 4 (4): e236–e246. doi:10.1016/S2666-5247(22)00390-1. PMC 9974155. PMID 36868258.
- Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. (September 2021). "Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (37): 1284–1290. doi:10.15585/mmwr.mm7037e1. PMC 8445374. PMID 34529637.
- Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K (August 2021). "Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021" (PDF). MMWR. Morbidity and Mortality Weekly Report. 70 (34): 1167–1169. doi:10.15585/mmwr.mm7034e4. PMC 8389394. PMID 34437521.
- Lee AR, Wong SY, Chai LY, Lee SC, Lee MX, Muthiah MD, et al. (March 2022). "Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis". BMJ. 376: e068632. doi:10.1136/bmj-2021-068632. PMC 8889026. PMID 35236664.
- Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL (August 2021). "Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies". Cancer Cell. 39 (8): 1031–1033. doi:10.1016/j.ccell.2021.07.012. PMC 8295014. PMID 34331856.
- Stein C, Nassereldine H, Sorensen RJ, Amlag JO, Bisignano C, Byrne S, et al. (February 2023). "Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis". The Lancet. 401 (10379): 833–842. doi:10.1016/S0140-6736(22)02465-5. ISSN 0140-6736. PMC 9998097. PMID 36930674.
- Payne AB (2024). "Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (1): 16–23. doi:10.15585/mmwr.mm7301a4. ISSN 0149-2195. PMC 10794061. PMID 38206877. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
- Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. (December 2021). "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months". The New England Journal of Medicine. 385 (24): e84. doi:10.1056/NEJMoa2114583. PMC 8522797. PMID 34614326.
- Wang R, Chen J, Wei GW (December 2021). "Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America" (PDF). The Journal of Physical Chemistry Letters. 12 (49): 11850–11857. doi:10.1021/acs.jpclett.1c03380. PMC 8672435. PMID 34873910. Archived (PDF) from the original on 18 December 2021. Retrieved 27 January 2022.
- Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. (February 2022). "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies". Nature. 602 (7898): 657–663. doi:10.1038/d41586-021-03796-6. PMC 8866119. PMID 35016194. S2CID 245455422.
- Mohsin M, Mahmud S (May 2022). "Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity". Medicine. 101 (19): e29165. doi:10.1097/MD.0000000000029165. PMC 9276130. PMID 35583528. S2CID 248858919.
- Shin DH, Smith DM, Choi JY (2022). "SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask". Yonsei Medical Journal. 63 (11): 977–983. doi:10.3349/ymj.2022.0383. PMC 9629902. PMID 36303305.
- Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. (February 2022). "Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study". The Lancet. Infectious Diseases. 22 (2): 183–195. doi:10.1016/S1473-3099(21)00648-4. PMC 8554486. PMID 34756186.
- Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N (April 2022). "COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts". Journal of Medical Virology. 94 (4): 1294–1299. doi:10.1002/jmv.27463. PMC 8661746. PMID 34796525.
- Al-Haideri MT, Mannani R, Kaboli R, Gharebakhshi F, Darvishzadehdeldari S, Tahmasebi S, et al. (August 2023). "The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence". Transplant Immunology. 79: 101858. doi:10.1016/j.trim.2023.101858. PMC 10205646. PMID 37236514.
- Kouhpayeh H, Ansari H (August 2022). "Adverse events following COVID-19 vaccination: A systematic review and meta-analysis". International Immunopharmacology. 109: 108906. doi:10.1016/j.intimp.2022.108906. PMC 9148928. PMID 35671640.
- Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, et al. (December 2022). "Efficacy and safety of COVID-19 vaccines". The Cochrane Database of Systematic Reviews. 12 (12): CD015477. doi:10.1002/14651858.CD015477. PMC 9726273. PMID 36473651.
- Haas JW, Bender FL, Ballou S, Kelley JM, Wilhelm M, Miller FG, et al. (January 2022). "Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis". JAMA Network Open. 5 (1): e2143955. doi:10.1001/jamanetworkopen.2021.43955. PMC 8767431. PMID 35040967.
- Polania Gutierrez JJ, Munakomi S (January 2020). "Intramuscular Injection". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32310581. Archived from the original on 8 December 2020. Retrieved 24 July 2021.
- Huang Z, Su Y, Zhang T, Xia N (February 2022). "A review of the safety and efficacy of current COVID-19 vaccines". Frontiers of Medicine. 16 (1): 39–55. doi:10.1007/s11684-021-0893-y. PMC 8815389. PMID 35122210.
- Tu W, Gierada DS, Joe BN (May 2021). "COVID-19 Vaccination-Related Lymphadenopathy: What To Be Aware Of". Radiology. Imaging Cancer. 3 (3): e210038. doi:10.1148/rycan.2021210038. PMC 8049171. PMID 33874733.
- Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. (October 2021). "Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military". JAMA Cardiology. 6 (10): 1202–06. doi:10.1001/jamacardio.2021.2833. PMC 8243257. PMID 34185045.
- Frontera JA, Tamborska AA, Doheim MF, Garcia-Azorin D, Gezegen H, Guekht A, et al. (March 2022). "Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS". Annals of Neurology. 91 (6): 756–771. doi:10.1002/ana.26339. PMC 9082459. PMID 35233819.
- Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. (December 2021). "Myocarditis after Covid-19 Vaccination in a Large Health Care Organization". The New England Journal of Medicine. 385 (23): 2132–2139. doi:10.1056/NEJMoa2110737. PMC 8531986. PMID 34614329. S2CID 238421512.
- Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. (September 2022). "Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex". Circulation. 146 (10): 743–754. doi:10.1161/CIRCULATIONAHA.122.059970. PMC 9439633. PMID 35993236.
- Jafari Z, Kolb BE, Mohajerani MH (March 2022). "Hearing Loss, Tinnitus, and Dizziness in COVID-19: A Systematic Review and Meta-Analysis". The Canadian Journal of Neurological Sciences. 49 (2): 184–195. doi:10.1017/cjn.2021.63. PMC 8267343. PMID 33843530.
- Dorney I, Bobak L, Otteson T, Kaelber DC (September 2022). "Prevalence of New-Onset Tinnitus after COVID-19 Vaccination with Comparison to Other Vaccinations". The Laryngoscope. 133 (7): 1722–1725. doi:10.1002/lary.30395. PMC 9539087. PMID 36098476.
- The Lancet Infectious Diseases Editors (September 2021). "COVID-19 vaccine equity and booster doses". The Lancet Infectious Diseases. 21 (9): 1193. doi:10.1016/S1473-3099(21)00486-2. PMC 8360703. PMID 34391506.
- Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR Morb Mortal Wkly Rep. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 9 June 2021.
nihr.ac.uk
evidence.nihr.ac.uk
- "Vaccines reduce the risk of long COVID". NIHR Evidence. 2024. doi:10.3310/nihrevidence_63203.
- "A pause in methotrexate treatment boosted the immune response to the COVID-19 vaccine". NIHR Evidence. National Institute for Health and Care Research. 26 January 2023. doi:10.3310/nihrevidence_56391.
nikkei.com
asia.nikkei.com
- Takada N, Satake M (2 May 2020). "US and China unleash wallets in race for coronavirus vaccine". Nikkei Asian Review. Archived from the original on 10 May 2020. Retrieved 3 May 2020.
nobelprize.org
- "The Nobel Prize in Physiology or Medicine 2023". NobelPrize.org. Archived from the original on 4 October 2023. Retrieved 3 October 2023.
- "The Nobel Prize in Physiology or Medicine 2023". NobelPrize.org. Archived from the original on 4 February 2024. Retrieved 3 October 2023.
novavax.com
- "Urgent global health needs addressed by Novavax". Novavax. Archived from the original on 12 May 2021. Retrieved 30 January 2021.
npr.org
- Palca J (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
nst.com.my
- Agencies (29 April 2024). "Report: AstraZeneca admitted in court doc that Covid vaccine can cause rare side effect [NSTTV] | New Straits Times". NST Online. Archived from the original on 30 April 2024. Retrieved 29 April 2024.
nytimes.com
- "Pfizer and Moderna Vaccines Likely to Produce Lasting Immunity, Study Finds". The New York Times. 28 June 2021. Archived from the original on 28 June 2021. Retrieved 23 January 2022.
- Corum J, Carl Z (8 January 2021). "How Gamaleya's Vaccine Works". The New York Times. Archived from the original on 20 April 2021. Retrieved 27 January 2021.
- Sanger DE, Kirkpatrick DD, Zimmer C, Thomas K, Wee SL (2 May 2020). "With Pressure Growing, Global Race for a Vaccine Intensifies". The New York Times. ISSN 0362-4331. Archived from the original on 11 May 2020. Retrieved 2 May 2020.
- Wee SL (4 May 2020). "China's coronavirus vaccine drive empowers a troubled industry". The New York Times. ISSN 0362-4331. Archived from the original on 4 May 2020. Retrieved 4 May 2020.
- Kramer AE (19 September 2020). "Russia Is Slow to Administer Virus Vaccine Despite Kremlin's Approval". The New York Times. ISSN 0362-4331. Archived from the original on 27 September 2020. Retrieved 28 September 2020.
- Mueller B (2 December 2020). "U.K. Approves Pfizer Coronavirus Vaccine, a First in the West". The New York Times. Archived from the original on 28 January 2021. Retrieved 2 December 2020.
- Thomas K, LaFraniere S, Weiland N, Goodnough A, Haberman M (12 December 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". The New York Times. Archived from the original on 12 December 2020. Retrieved 12 December 2020.
- Corum J, Zimmer C (17 December 2020). "How the Oxford-AstraZeneca Vaccine Works". The New York Times. Archived from the original on 5 January 2022. Retrieved 2 May 2021.
- Rasgon A (4 February 2021). "Israel's Vaccine Success Unleashes a Debate on Palestinian Inequities". The New York Times. Archived from the original on 28 December 2021. Retrieved 17 February 2021.
- Goodman PS, Mandavilli A, Robbins R, Stevis-Gridneff M (15 May 2021). "What Would It Take to Vaccinate the World Against Covid?". The New York Times. ISSN 0362-4331. Archived from the original on 15 May 2021. Retrieved 17 May 2021.
- Levin D (1 August 2021). "The U.S. is wasting vaccine doses, even as cases rise and other countries suffer shortages". The New York Times. Archived from the original on 9 August 2021. Retrieved 10 August 2021.
- Leonhardt D (11 March 2024). "The Fourth Anniversary of the Covid Pandemic". The New York Times. Archived from the original on 11 March 2024. "Data excludes Alaska. Sources: C.D.C. Wonder; Edison Research. (Chart) By The New York Times. Source credits chart to Ashley Wu.
ourworldindata.org
- "(OWID) vaccination maps". Our World in Data. Archived from the original on 21 December 2021. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. (5 March 2020). "Data FAQ". Our World in Data. Archived from the original on 10 March 2021.
- Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (March 2020). "Coronavirus (COVID-19) Vaccinations – Statistics and Research". Our World in Data. Archived from the original on 10 March 2021. Retrieved 7 February 2021.
- "Data on COVID-19 mortality by vaccination status". Our World in Data (CDC data). April 2023. Archived from the original on 16 October 2023.
Data source: Centers for Disease Control and Prevention, Vaccine Breakthrough/Surveillance and Analytics Team.
- Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. (2020–2024). "Coronavirus Pandemic (COVID-19)". Our World in Data. Retrieved 17 November 2024.
- Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. (2020). "Coronavirus Pandemic (COVID-19)". Our World in Data. Retrieved 14 November 2023.
- Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (1 September 2021). "Coronavirus (COVID-19) Vaccinations - Statistics and Research". Our World in Data. Archived from the original on 10 March 2021. Retrieved 26 January 2021.
oxfam.org
- "Vaccine monopolies make cost of vaccinating the world against COVID at least 5 times more expensive than it could be" (Press release). Oxfam International. 29 July 2021. Archived from the original on 10 January 2022. Retrieved 20 August 2021.
- "More than 140 former heads of state and Nobel laureates call on candidates for German chancellor to waive intellectual property rules for COVID-19 vaccines". Oxfam International (Press release). 14 September 2021. Archived from the original on 19 October 2021. Retrieved 22 September 2021.
pfizer.com
- "Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine". Pfizer (Press release). 20 November 2020. Archived from the original on 29 January 2021. Retrieved 20 November 2020.
pharmaceutical-technology.com
- Barrie R (31 March 2023). "Hipra's Covid-19 booster gets EMA nod and enters an uncertain landscape". Pharmaceutical Technology. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
pharmafield.co.uk
- Morriss E (22 April 2020). "Government launches coronavirus vaccine taskforce as human clinical trials start". Pharmafield. Archived from the original on 26 June 2020. Retrieved 3 May 2020.
phe.gov
- Azar A (4 February 2020). "Notice of Declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID-19". Archived from the original on 25 April 2020. Retrieved 22 April 2020.
pib.gov.in
- "Aarogya Setu is now open source". pib.gov.in (Press release). 26 May 2020. Archived from the original on 26 June 2020. Retrieved 18 July 2023.
precisionnanomedicine.com
- Hunziker P (July 2021). "Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit". Precision Nanomedicine. 4 (3): 805–820. doi:10.33218/001c.26101. Archived from the original on 9 October 2021. Retrieved 16 August 2021.
precisionvaccinations.com
- "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Archived from the original on 13 January 2021. Retrieved 11 January 2021.
publishing.service.gov.uk
assets.publishing.service.gov.uk
- SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 31 (PDF) (Briefing). Public Health England. 10 December 2021. pp. 3–5, 20–22. GOV-10645. Archived (PDF) from the original on 18 December 2021. Retrieved 10 December 2021.
reuters.com
- "Hungarian and US scientists win Nobel for COVID-19 vaccine discoveries". Reuters. 2 October 2023. Archived from the original on 8 October 2023. Retrieved 3 October 2023.
- Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Archived from the original on 28 February 2021. Retrieved 11 April 2021.
- "Kazakhstan rolls out its own COVID-19 vaccine". Reuters. 27 April 2021. Archived from the original on 4 November 2021. Retrieved 2 July 2021.
- "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
- Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.
- Tétrault-Farber M, Vasilyeva G (31 March 2021). "Russia registers world's first COVID-19 vaccine for animals". Reuters. Archived from the original on 17 December 2021. Retrieved 4 April 2021.
- Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.
- Blenkinsop P, Maclean W, Ellis A (10 March 2021). "Rich, developing nations wrangle over COVID vaccine patents". Reuters. Archived from the original on 11 March 2021. Retrieved 19 June 2021.
- Psaledakis D (22 September 2021). "Developing nations' plea to world's wealthy at U.N.: stop vaccine hoarding". Reuters. Archived from the original on 10 November 2021. Retrieved 29 September 2021.
- Jonathan S (30 November 2023). "Pfizer is sued by Texas over COVID vaccine claims". Reuters.
- Pierson B (18 June 2024). "Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit". Reuters.
- "Blackwater founder Prince takes role in COVID vaccine venture". Reuters. 4 June 2021. Archived from the original on 9 October 2021. Retrieved 4 June 2021.
- Bing C, Schechtman J (14 June 2024). "Pentagon Ran Secret Anti-Vax Campaign to Undermine China during Pandemic". Reuters.
scientificamerican.com
- Lewis T. "The New COVID Booster Shot Could Save Your Life; Get One Now, FDA Expert Says". Scientific American. Archived from the original on 7 November 2022. Retrieved 8 November 2022.
- Bottazzi ME, Hotez PJ (30 December 2021). "A COVID Vaccine for All". Scientific American. Archived from the original on 30 December 2021. Retrieved 19 January 2022.
- Mullin E (9 June 2021). "A 'Universal' Coronavirus Vaccine to Prevent the Next Pandemic". Scientific American. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
scmp.com
- Jeong-ho L, Zheng W, Zhou L (26 January 2020). "Chinese scientists race to develop vaccine as coronavirus death toll jumps". South China Morning Post. Archived from the original on 26 January 2020. Retrieved 28 January 2020.
- "WHO 'backed China's emergency use' of experimental Covid-19 vaccines". South China Morning Post. 25 September 2020. Archived from the original on 26 September 2020. Retrieved 26 September 2020.
- "WHO says against proof of Covid-19 vaccination for international travel". South China Morning Post. 20 April 2021. Archived from the original on 3 May 2021. Retrieved 17 May 2021.
semanticscholar.org
api.semanticscholar.org
- Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Van Noorden R (December 2021). "How COVID vaccines shaped 2021 in eight powerful charts". Nature. 600 (7890): 580–583. Bibcode:2021Natur.600..580M. doi:10.1038/d41586-021-03686-x. PMID 34916666. S2CID 245262732.
- Wang H, Xu R, Qu S, Schwartz M, Adams A, Chen X (October 2021). "Health inequities in COVID-19 vaccination among the elderly: Case of Connecticut". Journal of Infection and Public Health. 14 (10): 1563–1565. doi:10.1016/j.jiph.2021.07.013. PMC 8491089. PMID 34326008. S2CID 236515442.
- Mullard A (November 2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811.
- Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. ISSN 0066-4219. PMID 34637324. S2CID 238747462.
- Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
- Krammer F (October 2020). "SARS-CoV-2 vaccines in development". Nature. 586 (7830): 516–527. Bibcode:2020Natur.586..516K. doi:10.1038/s41586-020-2798-3. PMID 32967006. S2CID 221887746.
- Verbeke R, Lentacker I, De Smedt SC, Dewitte H (October 2019). "Three decades of messenger RNA vaccine development". Nano Today. 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. S2CID 202221207. Archived from the original on 9 October 2021. Retrieved 17 January 2021.
- Petrovsky N, Aguilar JC (October 2004). "Vaccine adjuvants: current state and future trends". Immunology and Cell Biology. 82 (5): 488–496. doi:10.1111/j.0818-9641.2004.01272.x. PMID 15479434. S2CID 154670.
- Waltz E (September 2022). "China and India approve nasal COVID vaccines - are they a game changer?". Nature. 609 (7927): 450. Bibcode:2022Natur.609..450W. doi:10.1038/d41586-022-02851-0. PMID 36071228. S2CID 252121594.
- Zabaleta N, Dai W, Bhatt U, Hérate C, Maisonnasse P, Chichester JA, et al. (August 2021). "An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates". Cell Host & Microbe. 29 (9): 1437–1453.e8. doi:10.1016/j.chom.2021.08.002. PMC 8346325. PMID 34428428. S2CID 231676030.
- Thorp HH (March 2020). "Underpromise, overdeliver". Science. 367 (6485): 1405. Bibcode:2020Sci...367.1405T. doi:10.1126/science.abb8492. PMID 32205459. S2CID 214628067.
- Cohen J (June 2020). "Pandemic vaccines are about to face the real test". Science. 368 (6497): 1295–96. Bibcode:2020Sci...368.1295C. doi:10.1126/science.368.6497.1295. PMID 32554572. S2CID 219911109.
- Warkentin TE, Pai M (October 2021). "Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res 2021 in press". Thrombosis Research. 207: 158–160. doi:10.1016/j.thromres.2021.10.007. PMID 34757250. S2CID 239574011.
We believe the name "VITT" works well … the term clearly denotes the key features of the disorder … provides a useful mnemonic for disease recognition in the usual sequence of events … need not mandate that thrombosis be present … "TTS" … has limited clinical utility, since many conditions … present with the duad of thrombosis and thrombocytopenia
- Le TT, Cramer JP, Chen R, Mayhew S (October 2020). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery. 19 (10): 667–668. doi:10.1038/d41573-020-00151-8. PMID 32887942. S2CID 221503034.
- Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
- Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. (February 2022). "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies". Nature. 602 (7898): 657–663. doi:10.1038/d41586-021-03796-6. PMC 8866119. PMID 35016194. S2CID 245455422.
- Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. (February 2022). "Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2". Nature. 602 (7898): 676–681. doi:10.1038/d41586-021-03826-3. PMID 35016198. S2CID 245462866.
- Mohsin M, Mahmud S (May 2022). "Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity". Medicine. 101 (19): e29165. doi:10.1097/MD.0000000000029165. PMC 9276130. PMID 35583528. S2CID 248858919.
- Callaway E (October 2021). "Mix-and-match COVID vaccines ace the effectiveness test". Nature. doi:10.1038/d41586-021-02853-4. PMID 34675430. S2CID 239455075.
- Male V (January 2022). "Menstruation and covid-19 vaccination". BMJ. 376: o142. doi:10.1136/bmj.o142. hdl:10044/1/94577. PMID 35082132. S2CID 246287912.
- Altmann DM, Boyton RJ (March 2022). "COVID-19 vaccination: The road ahead". Science. 375 (6585): 1127–1132. Bibcode:2022Sci...375.1127A. doi:10.1126/science.abn1755. PMID 35271316. S2CID 247384207.
- Basso C (October 2022). "Myocarditis". The New England Journal of Medicine. 387 (16): 1488–1500. doi:10.1056/NEJMra2114478. hdl:11577/3479721. PMID 36260793. S2CID 240234869.
- Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. (December 2021). "Myocarditis after Covid-19 Vaccination in a Large Health Care Organization". The New England Journal of Medicine. 385 (23): 2132–2139. doi:10.1056/NEJMoa2110737. PMC 8531986. PMID 34614329. S2CID 238421512.
- Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. (April 2022). "New-onset autoimmune phenomena post-COVID-19 vaccination". Immunology. 165 (4): 386–401. doi:10.1111/imm.13443. PMID 34957554. S2CID 245522029.
- Slomski A (May 2022). "Studies Examine Risk of Hearing Loss After COVID-19 Vaccination". JAMA. 327 (17): 1641. doi:10.1001/jama.2022.6719. PMID 35503358. S2CID 248502943.
- Mahase E (July 2021). "Covid-19: Countries dump vaccines as demand slumps and sharing proves difficult". BMJ. 374: n1893. doi:10.1136/bmj.n1893. PMID 34315725. S2CID 236457553.
- "The WHO is right to call a temporary halt to COVID vaccine boosters". Nature. 596 (7872): 317. August 2021. Bibcode:2021Natur.596..317.. doi:10.1038/d41586-021-02219-w. PMID 34404945. S2CID 237199262.
- Baraniuk C (February 2021). "Covid-19: How the UK vaccine rollout delivered success, so far". BMJ. 372: n421. doi:10.1136/bmj.n421. PMID 33602672. S2CID 231946710.
seruminstitute.com
- "ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) - Covishield". Serum Institute Of India. Archived from the original on 19 April 2021. Retrieved 16 April 2021.
shinyapps.io
vac-lshtm.shinyapps.io
- "COVID-19 vaccine tracker (Refresh URL to update)". London School of Hygiene & Tropical Medicine. 12 July 2021. Archived from the original on 11 October 2020. Retrieved 10 March 2021.
- "COVID-19 vaccine tracker (Refresh URL to update)". vac-lshtm.shinyapps.io. London School of Hygiene & Tropical Medicine. 12 July 2021. Retrieved 10 March 2021.
sibmeda.ru
- Maksimova K. "A scientist at the Gamaleya Center spoke about the benefits of a nasal vaccine against coronavirus". sibmeda.ru. Retrieved 5 June 2024.
sky.com
news.sky.com
- "COVID-19: WHO calls on countries to vaccinate 70% of their population by mid-2022". 29 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
sputnikvaccine.com
- "Single dose vaccine, Sputnik Light, authorized for use in Russia". Sputnik V (Press release). Archived from the original on 14 November 2021. Retrieved 12 August 2021.
statnews.com
- Chen J (4 May 2020). "Covid-19 has shuttered labs. It could put a generation of researchers at risk". Stat. Archived from the original on 6 May 2020. Retrieved 4 May 2020.
- Ahmed DD (4 June 2020). "Oxford, AstraZeneca COVID-19 deal reinforces 'vaccine sovereignty'". Stat. Archived from the original on 12 June 2020. Retrieved 8 June 2020.
swissmedic.ch
- "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 18 December 2020. Archived from the original on 2 May 2021. Retrieved 5 July 2022.
tass.ru
- "В России зарегистрировали первую в мире вакцину против COVID-19 для животных" [The world's first COVID-19 vaccine for animals was registered in Russia]. TASS (in Russian). Moscow. 31 March 2021. Archived from the original on 19 May 2021. Retrieved 19 May 2021.
technologyreview.com
- "Two inhaled covid vaccines have been approved—but we don't know yet how good they are". MIT Technology Review. Archived from the original on 21 October 2022. Retrieved 21 October 2022.
tehrantimes.com
- "Iran-Cuba vaccine enters phase three clinical trials". Tehran Times. 26 April 2021. Archived from the original on 19 July 2021. Retrieved 7 September 2021.
- "Two homegrown vaccines receive emergency use license". Tehran Times. 1 November 2021. Retrieved 5 June 2024.
telegraph.co.uk
- Gartner A, Roberts L (3 May 2020). "How close are we to a coronavirus vaccine? Latest news on UK trials". The Telegraph. ISSN 0307-1235. Archived from the original on 4 May 2020. Retrieved 3 May 2020.
texastribune.org
- Harper KB (30 November 2023). "Texas attorney general sues Pfizer, claiming vaccines didn't end pandemic quickly enough". The Texas Tribune.
tga.gov.au
- "Nonclinical Evaluation Report: BNT162b2 [mRNA] COVID-19 vaccine" (PDF). Australian Department of Health: Therapeutic Goods Administration. Archived (PDF) from the original on 28 March 2023. Retrieved 25 March 2023.
theconversation.com
- Grenfell R, Drew T (14 February 2020). "Here's why the WHO says a coronavirus vaccine is 18 months away". Business Insider. Archived from the original on 5 December 2020. Retrieved 11 November 2020.
theglobeandmail.com
- "G20 launches initiative for health tools needed to combat the coronavirus". The Globe and Mail. 25 April 2020. Archived from the original on 27 April 2020. Retrieved 1 February 2021.
theguardian.com
- Beaumont P (18 November 2020). "Covid-19 vaccine: who are countries prioritising for first doses?". The Guardian. ISSN 0261-3077. Archived from the original on 18 January 2021. Retrieved 26 December 2020.
- Devlin H (18 March 2022). "Covid immunity declines steeply in care home residents in England – study". The Guardian. Archived from the original on 23 March 2022. Retrieved 12 May 2022.
- Holmes O (16 February 2021). "Israel blocked Covid vaccines from entering Gaza, say Palestinians". The Guardian. Archived from the original on 16 February 2021. Retrieved 17 February 2021.
- Tapper J, McKie R (3 July 2021). "Vaccines 'outpaced by variants', WHO warns, as Delta now in 98 countries". The Guardian. Archived from the original on 21 October 2021. Retrieved 5 July 2021.
- Stiglitz J (15 December 2021). "If Olaf Scholz is serious about progress, he must back a patent waiver for Covid vaccines". The Guardian. Archived from the original on 15 December 2021. Retrieved 15 December 2021.
- Walker P (29 November 2021). "Nursing unions around world call for UN action on Covid vaccine patents". The Guardian. Archived from the original on 29 November 2021. Retrieved 29 November 2021.
- Elliott L (5 October 2021). "IMF cuts global economic forecast as pandemic 'hobbles' growth". The Guardian. Archived from the original on 27 October 2021. Retrieved 6 October 2021.
- "Florida governor seeks grand jury investigation into Covid vaccines". www.theguardian.com. 13 December 2022. Archived from the original on 13 December 2022. Retrieved 14 December 2022.
time.com
- Park A (20 November 2020). "Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA". Time. Archived from the original on 29 January 2021. Retrieved 20 November 2020.
trackvaccines.org
covid19.trackvaccines.org
- "Approved Vaccines". COVID 19 Vaccine Tracker, McGill University. 12 July 2021.
ugent.be
biblio.ugent.be
- Verbeke R, Lentacker I, De Smedt SC, Dewitte H (October 2019). "Three decades of messenger RNA vaccine development". Nano Today. 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. S2CID 202221207. Archived from the original on 9 October 2021. Retrieved 17 January 2021.
ukgm.de
- "Spezialsprechstunde Post-Vax" [Post-Vac Special Consultation]. Universitätsklinikum Giessen und Marburg (UKGM) (in German). Archived from the original on 4 May 2023.
umn.edu
cidrap.umn.edu
- Schnirring L (17 May 2021). "UN agencies make urgent appeal for COVAX vaccine doses". CIDRAP. Archived from the original on 31 October 2021. Retrieved 15 June 2021.
un.org
news.un.org
- "UN analysis shows a link between lack of vaccine equity and widening poverty gap". UN News. 28 March 2022. Archived from the original on 12 April 2022. Retrieved 14 April 2022.
- "COVID vaccines: Widening inequality and millions vulnerable". United Nations. 19 September 2021. Archived from the original on 31 December 2021. Retrieved 30 October 2021.
- "Refugees face dire consequences from COVID-19 underfunding, UNHCR warns". United Nations. 17 September 2021. Archived from the original on 30 October 2021. Retrieved 30 October 2021.
undp.org
data.undp.org
- "Impact of vaccine inequity on economic recovery". UN Development program. Archived from the original on 3 November 2021. Retrieved 30 October 2021.
vaccine-safety-training.org
- "Module 2 – Subunit vaccines". WHO Vaccine Safety Basics. Archived from the original on 8 August 2021. Retrieved 17 January 2021.
vaccines.gov
- "Vaccine Safety – Vaccines". US Department of Health and Human Services. Archived from the original on 22 April 2020. Retrieved 13 April 2020.
washingtonpost.com
- Johnson C, McGinley L. "Johnson & Johnson seeks emergency FDA authorization for single-shot coronavirus vaccine". The Washington Post. Archived from the original on 5 February 2021. Retrieved 10 February 2021.
- Johnson CY, Mufson S (11 June 2020). "Can old vaccines from science's medicine cabinet ward off coronavirus?". The Washington Post. ISSN 0190-8286. Archived from the original on 11 June 2020. Retrieved 31 December 2020.
web.archive.org
- "(OWID) vaccination maps". Our World in Data. Archived from the original on 21 December 2021. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. (5 March 2020). "Data FAQ". Our World in Data. Archived from the original on 10 March 2021.
- Rogers K (11 May 2022). "COVID-19 vaccine". Encyclopædia Britannica. Archived from the original on 12 June 2022. Retrieved 12 June 2022.
- "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 18 December 2020. Archived from the original on 2 May 2021. Retrieved 5 July 2022.
- "EMA recommends first COVID-19 vaccine for authorisation in the EU". European Medicines Agency (EMA) (Press release). 21 December 2020. Archived from the original on 30 January 2021. Retrieved 21 December 2020.
- Beaumont P (18 November 2020). "Covid-19 vaccine: who are countries prioritising for first doses?". The Guardian. ISSN 0261-3077. Archived from the original on 18 January 2021. Retrieved 26 December 2020.
- Background document on the mRNA-1273 vaccine (Moderna) against COVID-19 (Report). World Health Organization (WHO). February 2021. hdl:10665/339218. WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1. Archived from the original on 13 June 2021. Retrieved 24 July 2021.
- "Background document on the mRNA-1273 vaccine (Moderna) against COVID-19". World Health Organization (WHO). Archived from the original on 26 January 2022. Retrieved 23 January 2022.
- "Pregnancy, breastfeeding, fertility and coronavirus (COVID-19) vaccination". NHS. 5 October 2022. Archived from the original on 15 October 2022. Retrieved 15 October 2022.
- Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (March 2020). "Coronavirus (COVID-19) Vaccinations – Statistics and Research". Our World in Data. Archived from the original on 10 March 2021. Retrieved 7 February 2021.
- "The Nobel Prize in Physiology or Medicine 2023". NobelPrize.org. Archived from the original on 4 October 2023. Retrieved 3 October 2023.
- "Hungarian and US scientists win Nobel for COVID-19 vaccine discoveries". Reuters. 2 October 2023. Archived from the original on 8 October 2023. Retrieved 3 October 2023.
- "The Nobel Prize in Physiology or Medicine 2023". NobelPrize.org. Archived from the original on 4 February 2024. Retrieved 3 October 2023.
- Gates B (30 April 2020). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.
- "SARS (severe acute respiratory syndrome)". National Health Service. 5 March 2020. Archived from the original on 9 March 2020. Retrieved 31 January 2020.
- Loftus P, Hopkins JS, Pancevski B (17 November 2020). "Moderna and Pfizer Are Reinventing Vaccines, Starting With Covid". The Wall Street Journal. Archived from the original on 6 November 2021. Retrieved 4 October 2021.
- Lewis T. "The New COVID Booster Shot Could Save Your Life; Get One Now, FDA Expert Says". Scientific American. Archived from the original on 7 November 2022. Retrieved 8 November 2022.
- "Pfizer and Moderna Vaccines Likely to Produce Lasting Immunity, Study Finds". The New York Times. 28 June 2021. Archived from the original on 28 June 2021. Retrieved 23 January 2022.
- "COVID-19 vaccine tracker (Refresh URL to update)". London School of Hygiene & Tropical Medicine. 12 July 2021. Archived from the original on 11 October 2020. Retrieved 10 March 2021.
- Cross R (29 September 2020). "The tiny tweak behind COVID-19 vaccines". Chemical & Engineering News. Vol. 98, no. 38. Archived from the original on 16 February 2021. Retrieved 15 April 2021.
- Verbeke R, Lentacker I, De Smedt SC, Dewitte H (October 2019). "Three decades of messenger RNA vaccine development". Nano Today. 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. S2CID 202221207. Archived from the original on 9 October 2021. Retrieved 17 January 2021.
- "COVID-19 ACIP Vaccine Recommendations". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 3 November 2021. Retrieved 18 February 2021.
- "Safe COVID-19 vaccines for Europeans". European Commission. Archived from the original on 4 November 2021. Retrieved 19 February 2021.
- "Regulatory Decision Summary – Pfizer–BioNTech COVID-19 Vaccine". Health Canada, Government of Canada. 9 December 2020. Archived from the original on 30 January 2021. Retrieved 9 December 2020.
- "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". ClinicalTrials.gov. 30 April 2020. NCT04368728. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults". EU Clinical Trials Register. 14 April 2020. EudraCT 2020-001038-36. Archived from the original on 22 April 2020. Retrieved 22 April 2020.
- "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". ClinicalTrials.gov. 14 July 2020. NCT04470427. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
- Palca J (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
- "CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60". CureVac (Press release). 30 June 2021. Archived from the original on 12 October 2021. Retrieved 2 July 2021.
- "What are viral vector-based vaccines and how could they be used against COVID-19?". Gavi, the Vaccine Alliance (GAVI). 2020. Archived from the original on 11 November 2021. Retrieved 26 January 2021.
- "Understanding Viral Vector COVID-19 Vaccines". U.S. Centers for Disease Control and Prevention (CDC). 13 April 2021. Archived from the original on 13 November 2021. Retrieved 19 April 2021.
- "Investigating a Vaccine Against COVID-19". ClinicalTrials.gov. 26 May 2020. NCT04400838. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19". EU Clinical Trials Register. 21 April 2020. EudraCT 2020-001228-32. Archived from the original on 5 October 2020. Retrieved 3 August 2020.
- Corum J, Carl Z (8 January 2021). "How Gamaleya's Vaccine Works". The New York Times. Archived from the original on 20 April 2021. Retrieved 27 January 2021.
- "A Study of Ad26.COV2.S in Adults". 4 August 2020. Archived from the original on 16 September 2020. Retrieved 23 August 2020.
- "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". US National Library of Medicine. Archived from the original on 26 September 2020.
- Johnson C, McGinley L. "Johnson & Johnson seeks emergency FDA authorization for single-shot coronavirus vaccine". The Washington Post. Archived from the original on 5 February 2021. Retrieved 10 February 2021.
- "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective". Fortune. Archived from the original on 8 August 2021. Retrieved 28 February 2021.
- "Single dose vaccine, Sputnik Light, authorized for use in Russia". Sputnik V (Press release). Archived from the original on 14 November 2021. Retrieved 12 August 2021.
- Sputnik V [@sputnikvaccine] (6 May 2021). "Introducing a new member of the Sputnik family - a single dose Sputnik Light! It's a revolutionary 1-shot COVID-19 vaccine with the 80% efficacy - higher than many 2-shot vaccines. Sputnik Light will double vaccination rates and help to handle epidemic peaks https://t.co/BCybe8yYWU" (Tweet). Archived from the original on 8 May 2022. Retrieved 8 December 2022 – via Twitter.
- "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
- PT. Bio Farma (August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
- Chen W, Al Kaabi N (July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
- Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Archived from the original on 28 February 2021. Retrieved 11 April 2021.
- "Kazakhstan rolls out its own COVID-19 vaccine". Reuters. 27 April 2021. Archived from the original on 4 November 2021. Retrieved 2 July 2021.
- "FarsNews Agency Iran Licenses Emergency Injection of Home-Made Anti-Coronavirus Vaccine". Fars News Agency. 14 June 2021. Archived from the original on 9 October 2021. Retrieved 25 August 2021.
- "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Archived from the original on 13 January 2021. Retrieved 11 January 2021.
- "Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactivated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults". U.S. National Library of Medicine. 30 December 2020. Archived from the original on 14 February 2021. Retrieved 11 January 2021.
- "Module 2 – Subunit vaccines". WHO Vaccine Safety Basics. Archived from the original on 8 August 2021. Retrieved 17 January 2021.
- "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)". ClinicalTrials.gov. 22 September 2020. NCT04368988. Archived from the original on 29 June 2021. Retrieved 16 November 2020.
- "MVC COVID-19 Vaccine Obtains Taiwan EUA Approval". Medigen Vaccine Biologics. Archived from the original on 27 November 2021. Retrieved 7 August 2021.
- Achom D (28 December 2021). "India Clears 2 New Vaccines And Merck's Covid Pill: 10 Points". NDTV.com. Archived from the original on 28 December 2021. Retrieved 19 January 2022.
- Bottazzi ME, Hotez PJ (30 December 2021). "A COVID Vaccine for All". Scientific American. Archived from the original on 30 December 2021. Retrieved 19 January 2022.
- "VidPrevtyn Beta". European Medicines Agency (EMA). 4 November 2022. Archived from the original on 11 November 2022. Retrieved 12 November 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "EMA recommends approval of VidPrevtyn Beta as a COVID-19 booster vaccine". European Medicines Agency (EMA) (Press release). 10 November 2022. Archived from the original on 12 November 2022. Retrieved 12 November 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Iran-Cuba vaccine enters phase three clinical trials". Tehran Times. 26 April 2021. Archived from the original on 19 July 2021. Retrieved 7 September 2021.
- Barrie R (31 March 2023). "Hipra's Covid-19 booster gets EMA nod and enters an uncertain landscape". Pharmaceutical Technology. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
- "Bimervax EPAR". European Medicines Agency. 5 April 2023. Archived from the original on 8 April 2023. Retrieved 9 April 2023.
- "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults". ClinicalTrials.gov. 3 August 2020. NCT04495933. Archived from the original on 11 October 2020. Retrieved 4 August 2020.
- "Australian vaccine trials stopped due to HIV false positives". Deutsche Welle. 11 December 2020. Archived from the original on 26 January 2021. Retrieved 9 January 2023.
- "Covid: Australian vaccine abandoned over false HIV response". BBC News Online. 11 December 2020. Archived from the original on 16 January 2021. Retrieved 9 April 2023.
- "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant". ClinicalTrials.gov. 30 April 2020. NCT04368988. Archived from the original on 14 July 2020. Retrieved 14 July 2020.
- "A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects". India: Clinical Trials Registry. 15 December 2020. CTRI/2020/07/026352. Archived from the original on 22 November 2020.
- "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". ClinicalTrials.gov. 7 April 2020. NCT04336410. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID‑19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Archived from the original on 24 September 2020. Retrieved 23 April 2020.
- "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
- Chang LJ (March 2020). "Safety and Immunity of Covid-19 aAPC Vaccine". ClinicalTrials.gov. NCT04299724. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine". ClinicalTrials.gov. February 2020. NCT04276896. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults". ClinicalTrials.gov. November 2020. NCT04608305. Archived from the original on 3 May 2021. Retrieved 2 January 2021.
- Johnson CY, Mufson S (11 June 2020). "Can old vaccines from science's medicine cabinet ward off coronavirus?". The Washington Post. ISSN 0190-8286. Archived from the original on 11 June 2020. Retrieved 31 December 2020.
- "Bacille Calmette-Guérin (BCG) vaccination and COVID-19". World Health Organization (WHO). 12 April 2020. Archived from the original on 30 April 2020. Retrieved 1 May 2020.
- "Urgent global health needs addressed by Novavax". Novavax. Archived from the original on 12 May 2021. Retrieved 30 January 2021.
- "Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine)". U.S. Centers for Disease Control and Prevention (CDC). 3 August 2021. Archived from the original on 14 October 2019. Retrieved 8 September 2021.
- "Two inhaled covid vaccines have been approved—but we don't know yet how good they are". MIT Technology Review. Archived from the original on 21 October 2022. Retrieved 21 October 2022.
- "Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection". ClinicalTrials.gov. 30 December 2020. Archived from the original on 13 May 2022. Retrieved 5 September 2022.
- "Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19". ClinicalTrials.gov. 16 August 2021. Archived from the original on 18 June 2022. Retrieved 5 September 2022.
- Mullin E (9 June 2021). "A 'Universal' Coronavirus Vaccine to Prevent the Next Pandemic". Scientific American. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
- Joi P (13 July 2021). "Could a universal coronavirus vaccine soon be a reality?". GAVI. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
- Bush E (15 December 2021). "Fauci pushes for universal coronavirus vaccine". NBC News. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
- "National COVID-19 Preparedness Plan" (PDF). The White House. March 2022. pp. 9, 21, 29. Archived from the original (PDF) on 26 March 2022. Retrieved 29 March 2022.
- "Phase 1 Clinical Trial of WRAIR-developed COVID-19 Vaccine Begins". 5 April 2022. Archived from the original on 11 July 2022. Retrieved 11 July 2022.
- Haridy R (7 July 2022). "Another universal coronavirus vaccine readies for human trials". New Atlas. Archived from the original on 11 July 2022. Retrieved 11 July 2022.
- Sanger DE, Kirkpatrick DD, Zimmer C, Thomas K, Wee SL (2 May 2020). "With Pressure Growing, Global Race for a Vaccine Intensifies". The New York Times. ISSN 0362-4331. Archived from the original on 11 May 2020. Retrieved 2 May 2020.
- Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.
- Jeong-ho L, Zheng W, Zhou L (26 January 2020). "Chinese scientists race to develop vaccine as coronavirus death toll jumps". South China Morning Post. Archived from the original on 26 January 2020. Retrieved 28 January 2020.
- Wee SL (4 May 2020). "China's coronavirus vaccine drive empowers a troubled industry". The New York Times. ISSN 0362-4331. Archived from the original on 4 May 2020. Retrieved 4 May 2020.
- Chen J (4 May 2020). "Covid-19 has shuttered labs. It could put a generation of researchers at risk". Stat. Archived from the original on 6 May 2020. Retrieved 4 May 2020.
- "Vaccine Safety – Vaccines". US Department of Health and Human Services. Archived from the original on 22 April 2020. Retrieved 13 April 2020.
- "The drug development process". U.S. Food and Drug Administration (FDA). 4 January 2018. Archived from the original on 22 February 2020. Retrieved 12 April 2020.
- Howard J, Stracqualursi V (18 June 2020). "Fauci warns of 'anti-science bias' being a problem in US". CNN. Archived from the original on 21 June 2020. Retrieved 21 June 2020.
- "Vaccines: The Emergency Authorisation Procedure". European Medicines Agency (EMA). 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
- Byrne J (19 October 2020). "Moderna COVID-19 vaccine under rolling review process in Canada, EU". BioPharma-Reporter.com, William Reed Business Media Ltd. Archived from the original on 25 February 2021. Retrieved 25 November 2020.
- Dangerfield K (20 November 2020). "Pfizer files for emergency use of coronavirus vaccine in U.S. – what about in Canada?". Global News. Archived from the original on 25 January 2021. Retrieved 25 November 2020.
- "G20 launches initiative for health tools needed to combat the coronavirus". The Globe and Mail. 25 April 2020. Archived from the original on 27 April 2020. Retrieved 1 February 2021.
- "Access to COVID-19 Tools (ACT) Accelerator" (PDF). World Health Organization (WHO). 24 April 2020. Archived (PDF) from the original on 25 April 2020. Retrieved 1 February 2021.
- "The ACT-Accelerator: frequently asked questions (FAQ)". World Health Organization (WHO). 2020. Archived from the original on 4 May 2021. Retrieved 16 December 2020.
- "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020.
It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months, and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
- Abedi M (23 March 2020). "Canada to spend $192M on developing COVID-19 vaccine". Global News. Archived from the original on 9 April 2020. Retrieved 24 March 2020.
- "Government of Canada's research response to COVID-19". Government of Canada. 23 April 2020. Archived from the original on 13 May 2020. Retrieved 4 May 2020.
- Takada N, Satake M (2 May 2020). "US and China unleash wallets in race for coronavirus vaccine". Nikkei Asian Review. Archived from the original on 10 May 2020. Retrieved 3 May 2020.
- Morriss E (22 April 2020). "Government launches coronavirus vaccine taskforce as human clinical trials start". Pharmafield. Archived from the original on 26 June 2020. Retrieved 3 May 2020.
- Kuznia R, Polglase K, Mezzofiore G (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. Archived from the original on 13 May 2020. Retrieved 2 May 2020.
- Sink J, Fabian J, Griffin R (15 May 2020). "Trump introduces 'Warp Speed' leaders to hasten COVID-19 vaccine". Bloomberg. Archived from the original on 21 May 2020. Retrieved 15 May 2020.
- LaHucik K (17 June 2021). "U.S. injects $3B-plus into COVID-19 research to develop antiviral pill within a year". Fierce Biotech. Archived from the original on 9 October 2021. Retrieved 11 July 2021.
- "Use of AstraZeneca COVID-19 vaccine in younger adults" (Press release). Health Canada. 29 March 2021. Archived from the original on 11 October 2021. Retrieved 2 April 2021.
- "AstraZeneca COVID-19 Vaccine (AZD1222)" (PDF). ACIP COVID-19 Emergency Meeting. AstraZeneca. 27 January 2021. Archived (PDF) from the original on 27 January 2021. Retrieved 16 April 2021.
- "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR". European Medicines Agency (EMA). 25 January 2021. Archived from the original on 21 April 2021. Retrieved 16 April 2021.
The name of the vaccine was changed to Vaxzevria on 25 March 2021.
Vaxzevria (COVID‑19 Vaccine (ChAdOx1-S recombinant) EMA/182334/2021 Archived 15 April 2021 at the Wayback Machine Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. - "ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) - Covishield". Serum Institute Of India. Archived from the original on 19 April 2021. Retrieved 16 April 2021.
- "AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine". World Health Organization (WHO). Archived from the original on 28 November 2021. Retrieved 28 November 2021.
- "COVID-19 vaccine safety update: Vaxzevria" (PDF). European Medicines Agency (EMA). 28 March 2021. Archived (PDF) from the original on 13 April 2021. Retrieved 31 March 2021.
- Marks P. "Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine". Archived from the original on 20 May 2021. Retrieved 13 April 2021.
- "Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals". U.S. Food and Drug Administration. 5 May 2022. Archived from the original on 7 May 2022. Retrieved 7 May 2022.
- Medical Director of AstraZeneca AB (13 April 2021). "Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia" (PDF). European Medicines Agency (EMA). Archived (PDF) from the original on 18 July 2022. Retrieved 13 April 2021.
- "Research and analysis — Coronavirus vaccine - weekly summary of Yellow Card reporting". Medicines and Healthcare products Regulatory Agency (MHRA). 1 April 2021. Archived from the original on 20 May 2021. Retrieved 3 April 2020.
- EMA (7 April 2021). EMA press conference 7th April — Conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of COVID-19 Vaccine AstraZeneca and thromboembolic events. European Medicines Agency (EMA). Archived from the original on 7 April 2021. Retrieved 7 April 2021 – via Youtube.
- Agencies (29 April 2024). "Report: AstraZeneca admitted in court doc that Covid vaccine can cause rare side effect [NSTTV] | New Straits Times". NST Online. Archived from the original on 30 April 2024. Retrieved 29 April 2024.
- "In a first, AstraZeneca admits its Covid vaccine can cause rare blood clots". The Independent. 30 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
- "World Health Organization timeline – COVID-19". World Health Organization (WHO). 27 April 2020. Archived from the original on 29 April 2020. Retrieved 2 May 2020.
- Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
- "COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert". CBC Radio. 8 May 2020. Archived from the original on 13 May 2020. Retrieved 8 June 2020.
- Ahmed DD (4 June 2020). "Oxford, AstraZeneca COVID-19 deal reinforces 'vaccine sovereignty'". Stat. Archived from the original on 12 June 2020. Retrieved 8 June 2020.
- Grenfell R, Drew T (14 February 2020). "Here's why the WHO says a coronavirus vaccine is 18 months away". Business Insider. Archived from the original on 5 December 2020. Retrieved 11 November 2020.
- Offit P (13 February 2021). "TWiV 720: With vaccines, Offit is on it". This Week in Virology Podcast. Vincent Racaniello Youtube Channel. Archived from the original on 25 May 2021. Retrieved 14 July 2021.
- "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020.
It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
- "WHO 'backed China's emergency use' of experimental Covid-19 vaccines". South China Morning Post. 25 September 2020. Archived from the original on 26 September 2020. Retrieved 26 September 2020.
- Kramer AE (19 September 2020). "Russia Is Slow to Administer Virus Vaccine Despite Kremlin's Approval". The New York Times. ISSN 0362-4331. Archived from the original on 27 September 2020. Retrieved 28 September 2020.
- "Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine". Pfizer (Press release). 20 November 2020. Archived from the original on 29 January 2021. Retrieved 20 November 2020.
- Park A (20 November 2020). "Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA". Time. Archived from the original on 29 January 2021. Retrieved 20 November 2020.
- "Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Archived from the original on 15 March 2021. Retrieved 13 December 2020.
- "Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 3 December 2020. Archived from the original on 26 February 2021. Retrieved 19 December 2020.
- "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Archived from the original on 17 March 2021. Retrieved 2 December 2020.
- Mueller B (2 December 2020). "U.K. Approves Pfizer Coronavirus Vaccine, a First in the West". The New York Times. Archived from the original on 28 January 2021. Retrieved 2 December 2020.
- Roberts M (2 December 2020). "Covid Pfizer vaccine approved for use next week in UK". BBC News Online. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
- "Questions and Answers: COVID-19 vaccination in the EU". European Commission. 21 December 2020. Archived from the original on 29 January 2021. Retrieved 21 December 2020.
- "Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine". Bahrain News Agency. 4 December 2020. Archived from the original on 17 December 2020. Retrieved 9 December 2020.
- "UAE: Ministry of Health announces 86 per cent vaccine efficacy". Gulf News. Archived from the original on 24 December 2020. Retrieved 9 December 2020.
- Thomas K, LaFraniere S, Weiland N, Goodnough A, Haberman M (12 December 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". The New York Times. Archived from the original on 12 December 2020. Retrieved 12 December 2020.
- "FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 17 March 2021. Retrieved 18 December 2020.
- Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152): 1653–56. doi:10.15585/mmwr.mm695152e1. PMC 9191904. PMID 33382675. S2CID 229945697. Archived (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
- Lovelace Jr B (19 December 2020). "FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution". CNBC. Archived from the original on 26 January 2021. Retrieved 19 December 2020.
- Corum J, Zimmer C (17 December 2020). "How the Oxford-AstraZeneca Vaccine Works". The New York Times. Archived from the original on 5 January 2022. Retrieved 2 May 2021.
- Tétrault-Farber M, Vasilyeva G (31 March 2021). "Russia registers world's first COVID-19 vaccine for animals". Reuters. Archived from the original on 17 December 2021. Retrieved 4 April 2021.
- "В России зарегистрировали первую в мире вакцину против COVID-19 для животных" [The world's first COVID-19 vaccine for animals was registered in Russia]. TASS (in Russian). Moscow. 31 March 2021. Archived from the original on 19 May 2021. Retrieved 19 May 2021.
- Taylor R (2 November 2021). "Sequences of Covid-19 vaccines released via WhatDoTheyKnow". mySociety. Archived from the original on 5 November 2021. Retrieved 2 November 2021.
- "Data on COVID-19 mortality by vaccination status". Our World in Data (CDC data). April 2023. Archived from the original on 16 October 2023.
Data source: Centers for Disease Control and Prevention, Vaccine Breakthrough/Surveillance and Analytics Team.
- Schreiber M, Chayka K, Chayka K, Beyerstein L, Beyerstein L, Wilson J, et al. (1 July 2021). "The Delta Covid Variant's Urgent Message for America". The New Republic. ISSN 0028-6583. Archived from the original on 28 August 2021. Retrieved 28 October 2021.
- "Among the unvaccinated, Delta variant more than doubles risk of hospitalization". Los Angeles Times. 28 August 2021. Archived from the original on 8 November 2021.
- SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 31 (PDF) (Briefing). Public Health England. 10 December 2021. pp. 3–5, 20–22. GOV-10645. Archived (PDF) from the original on 18 December 2021. Retrieved 10 December 2021.
- Payne AB (2024). "Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (1): 16–23. doi:10.15585/mmwr.mm7301a4. ISSN 0149-2195. PMC 10794061. PMID 38206877. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
- Mole B (12 January 2024). "COVID shots protect against COVID-related strokes, heart attacks, study finds". Ars Technica. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
- "Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity". Centers for Disease Control and Prevention (CDC). 29 October 2021. Archived from the original on 4 December 2021. Retrieved 4 December 2021. This article incorporates text from this source, which is in the public domain.
- "COVID-19 Booster Shot". Centers for Disease Control and Prevention. 29 November 2021. Archived from the original on 21 August 2021. Retrieved 4 December 2021.
- Devlin H (18 March 2022). "Covid immunity declines steeply in care home residents in England – study". The Guardian. Archived from the original on 23 March 2022. Retrieved 12 May 2022.
- Kimball S. "CDC recommends fourth Pfizer and Moderna Covid vaccine doses for people age 50 and older". CNBC. Archived from the original on 3 September 2022. Retrieved 22 August 2022.
- "Coronavirus Disease 2019". Centers for Disease Control and Prevention (Press release). 29 March 2022. Archived from the original on 1 September 2022. Retrieved 22 August 2022.
- Wang R, Chen J, Wei GW (December 2021). "Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America" (PDF). The Journal of Physical Chemistry Letters. 12 (49): 11850–11857. doi:10.1021/acs.jpclett.1c03380. PMC 8672435. PMID 34873910. Archived (PDF) from the original on 18 December 2021. Retrieved 27 January 2022.
- "Study findings suggest spread of Omicron can be ascribed to immune evasiveness rather than an increase in transmissibility". News-Medical.net. 5 January 2022. Archived from the original on 21 January 2022. Retrieved 17 January 2022.
- "How soon after catching COVID-19 can you get it again?". ABC News. 2 May 2022. Archived from the original on 9 July 2022. Retrieved 24 June 2022.
- "Omicron Variant: What You Need to Know". Centers for Disease Control and Prevention. 20 December 2021. Archived from the original on 27 January 2022. Retrieved 27 January 2022.
- "COVID-19 Vaccine Boosters". U.S. Food and Drug Administration (FDA). 27 September 2022. Archived from the original on 8 October 2022. Retrieved 8 October 2022.
- "Moderna COVID-19 Vaccines". U.S. Food and Drug Administration (FDA). 7 October 2022. Archived from the original on 7 October 2022. Retrieved 8 October 2022.
- "Pfizer-BioNTech COVID-19 Vaccines". U.S. Food and Drug Administration (FDA). 3 October 2022. Archived from the original on 8 October 2022. Retrieved 8 October 2022.
- "Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023". U.S. Food and Drug Administration (FDA). 15 June 2023. Archived from the original on 17 June 2023. Retrieved 16 June 2023. This article incorporates text from this source, which is in the public domain.
- Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the U.S. (PDF) (Report). U.S. Food and Drug Administration (FDA). 16 June 2023. Archived from the original on 16 June 2023. Retrieved 16 June 2023.
- "Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024". U.S. Food and Drug Administration (FDA). 5 June 2024. Archived from the original on 18 June 2024. Retrieved 19 June 2024. This article incorporates text from this source, which is in the public domain.
- Polania Gutierrez JJ, Munakomi S (January 2020). "Intramuscular Injection". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32310581. Archived from the original on 8 December 2020. Retrieved 24 July 2021.
- "Nonclinical Evaluation Report: BNT162b2 [mRNA] COVID-19 vaccine" (PDF). Australian Department of Health: Therapeutic Goods Administration. Archived (PDF) from the original on 28 March 2023. Retrieved 25 March 2023.
- "World Health Organization (WHO)". 17 September 2018. Archived from the original on 4 October 2023. Retrieved 19 September 2023.
- McDonald J (23 December 2021). "Increase in COVID-19 VAERS Reports Due To Reporting Requirements, Intense Scrutiny of Widely Given Vaccines". FactCheck.org. Archived from the original on 20 May 2022. Retrieved 20 May 2022.
- "Treating Post-Vac-Syndrome". Deutsche Welle. 11 October 2022. Archived from the original on 17 April 2023.
- "Spezialsprechstunde Post-Vax" [Post-Vac Special Consultation]. Universitätsklinikum Giessen und Marburg (UKGM) (in German). Archived from the original on 4 May 2023.
- "Corona-Impfschäden: Uniklinik Marburg öffnet eigene Ambulanz" [Corona vaccine damage: Marburg University Hospital opens its own outpatient clinic]. Frankfurter Allgemeine Zeitung GmbH (in German). 3 April 2023. Archived from the original on 8 March 2024.
- COVID-19 vaccines safety update (PDF) (Report). Archived (PDF) from the original on 3 August 2022. Retrieved 6 September 2022.
- Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (1 September 2021). "Coronavirus (COVID-19) Vaccinations - Statistics and Research". Our World in Data. Archived from the original on 10 March 2021. Retrieved 26 January 2021.
- "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020.
It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. The World Health Organization (WHO) is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
- Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
- Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.
- Gartner A, Roberts L (3 May 2020). "How close are we to a coronavirus vaccine? Latest news on UK trials". The Telegraph. ISSN 0307-1235. Archived from the original on 4 May 2020. Retrieved 3 May 2020.
- "WHO, UN set out steps to meet world COVID vaccination targets". World Health Organization (WHO). 7 October 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
- "COVID-19: WHO calls on countries to vaccinate 70% of their population by mid-2022". 29 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
- "Covid-19 vaccinations: African nations miss WHO target". BBC. 31 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
- Adhanom Ghebreyesus T (18 January 2021). "WHO Director-General's opening remarks at 148th session of the Executive Board". World Health Organization (WHO). Archived from the original on 12 November 2021. Retrieved 25 January 2021.
- "U.S. pressured Brazil to ditch Russia's Sputnik V vaccine". The Brazilian Report. 15 March 2021. Archived from the original on 15 March 2021. Retrieved 21 March 2021.
- Holmes O (16 February 2021). "Israel blocked Covid vaccines from entering Gaza, say Palestinians". The Guardian. Archived from the original on 16 February 2021. Retrieved 17 February 2021.
- Horton C (17 February 2021). "Taiwan Concerned China May Have Blocked Vaccine Purchase". Bloomberg. Archived from the original on 17 February 2021. Retrieved 17 February 2021.
- "Playing Politics with Poverty: Sisi's COVID-19 Vaccine Strategy". Carnegie Endowment for International Peace. Archived from the original on 28 February 2021. Retrieved 25 February 2021.
- Strazewski L (9 February 2021). "Dr. Fauci: Variants reveal COVID-19 vaccination as global job". American Medical Association. Archived from the original on 10 October 2021. Retrieved 4 March 2021.
- Bergmark E, Wierson A (26 February 2021). "Opinion: Without a global vaccine plan, coronavirus variants could lead to untold number of deaths". CNN. Archived from the original on 19 October 2021. Retrieved 4 March 2021.
- Blenkinsop P, Maclean W, Ellis A (10 March 2021). "Rich, developing nations wrangle over COVID vaccine patents". Reuters. Archived from the original on 11 March 2021. Retrieved 19 June 2021.
- Macias AM, Breuninger K, Franck (5 May 2021). "U.S. backs waiving patent protections for Covid vaccines, citing global health crisis". CNBC. Archived from the original on 5 May 2021. Retrieved 5 May 2021.
- Sánchez Nicolás E (11 June 2021). "Pressure builds on EU to back WTO vaccine-patent waiver". EUobserver. Archived from the original on 19 October 2021. Retrieved 14 June 2021.
- "WHO says against proof of Covid-19 vaccination for international travel". South China Morning Post. 20 April 2021. Archived from the original on 3 May 2021. Retrieved 17 May 2021.
- Goodman PS, Mandavilli A, Robbins R, Stevis-Gridneff M (15 May 2021). "What Would It Take to Vaccinate the World Against Covid?". The New York Times. ISSN 0362-4331. Archived from the original on 15 May 2021. Retrieved 17 May 2021.
- Muniz B, Fonseca B, Fernandes L, Pina R (15 March 2021). "Brasil registra duas vezes mais pessoas brancas vacinadas que negras" [Brazil registers twice as many white people vaccinated as black people]. Agência Pública (in Brazilian Portuguese). Archived from the original on 15 March 2021. Retrieved 28 May 2021.
- Schnirring L (17 May 2021). "UN agencies make urgent appeal for COVAX vaccine doses". CIDRAP. Archived from the original on 31 October 2021. Retrieved 15 June 2021.
- "First Meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries". World Health Organization (WHO). 30 June 2021. Archived from the original on 19 October 2021. Retrieved 5 July 2021.
- Tapper J, McKie R (3 July 2021). "Vaccines 'outpaced by variants', WHO warns, as Delta now in 98 countries". The Guardian. Archived from the original on 21 October 2021. Retrieved 5 July 2021.
- Levin D (1 August 2021). "The U.S. is wasting vaccine doses, even as cases rise and other countries suffer shortages". The New York Times. Archived from the original on 9 August 2021. Retrieved 10 August 2021.
- "Covid-19 vaccines: Why some African states can't use their vaccines". BBC News. 8 June 2021. Archived from the original on 14 November 2021. Retrieved 20 August 2021.
- Das S (5 July 2021). "CoWIN goes global: India makes tech open source, 142 nations show interest". Business Standard India. Archived from the original on 25 March 2022. Retrieved 25 March 2022.
- "Aarogya Setu is now open source". pib.gov.in (Press release). 26 May 2020. Archived from the original on 26 June 2020. Retrieved 18 July 2023.
- "G7 support for pharma monopolies is putting millions of lives at risk" (Press release). Amnesty International. 10 June 2021. Archived from the original on 19 October 2021. Retrieved 20 August 2021.
- "Vaccine monopolies make cost of vaccinating the world against COVID at least 5 times more expensive than it could be" (Press release). Oxfam International. 29 July 2021. Archived from the original on 10 January 2022. Retrieved 20 August 2021.
- Stiglitz J (15 December 2021). "If Olaf Scholz is serious about progress, he must back a patent waiver for Covid vaccines". The Guardian. Archived from the original on 15 December 2021. Retrieved 15 December 2021.
- "Countries must not let another opportunity slip by to advance the global waiver on overcoming COVID-19 medical-tool monopolies". Médecins Sans Frontières (MSF)/Doctors Without Borders. 13 September 2021. Archived from the original on 10 October 2021. Retrieved 23 September 2021.
- "MSF calls for no patents or profiteering on COVID-19 drugs and vaccines / No profiteering on COVID-19 drugs and vaccines, says MSF". Médecins Sans Frontières (MSF) International. Archived from the original on 26 November 2021. Retrieved 23 September 2021.
- "Governments must act fast on consensus supporting historic move to suspend monopolies during pandemic / COVID-19: Governments must build consensus around waiver". Médecins Sans Frontières (MSF) International. Archived from the original on 23 October 2021. Retrieved 23 September 2021.
- "WHO slams wealthy nations' rush towards Covid booster shots while millions worldwide lack first jab". France 24. Agence France-Presse. 18 August 2021. Archived from the original on 2 November 2021. Retrieved 21 August 2021.
- Kramer J (18 August 2021). "The U.S. plans to authorize boosters—but many already got a third dose". National Geographic. Archived from the original on 10 October 2021. Retrieved 21 August 2021.
- "More than 140 former heads of state and Nobel laureates call on candidates for German chancellor to waive intellectual property rules for COVID-19 vaccines". Oxfam International (Press release). 14 September 2021. Archived from the original on 19 October 2021. Retrieved 22 September 2021.
- Walker P (29 November 2021). "Nursing unions around world call for UN action on Covid vaccine patents". The Guardian. Archived from the original on 29 November 2021. Retrieved 29 November 2021.
- Psaledakis D (22 September 2021). "Developing nations' plea to world's wealthy at U.N.: stop vaccine hoarding". Reuters. Archived from the original on 10 November 2021. Retrieved 29 September 2021.
- Empresa Peruana de Servicios Editoriales S. A. EDITORA PERÚ (21 September 2021). "Peru: President suggests global agreement at UN ensuring universal access to vaccines". Andina (in Spanish). Archived from the original on 30 October 2021. Retrieved 29 September 2021.
- "Additional Dose of mRNA COVID‑19 Vaccine for Patients Who Are Immunocompromised". U.S. Centers for Disease Control and Prevention (CDC). 13 August 2021. Archived from the original on 7 October 2021. Retrieved 16 August 2021.
- "France plans rollout of Covid vaccine booster shots – but only for the vulnerable". France 24. 4 August 2021. Archived from the original on 22 October 2021. Retrieved 16 August 2021.
- "Israel to offer 3rd COVID booster shot to older citizens". Associated Press. 29 July 2021. Archived from the original on 31 October 2021. Retrieved 16 August 2021.
- Hunziker P (July 2021). "Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit". Precision Nanomedicine. 4 (3): 805–820. doi:10.33218/001c.26101. Archived from the original on 9 October 2021. Retrieved 16 August 2021.
- "UN analysis shows a link between lack of vaccine equity and widening poverty gap". UN News. 28 March 2022. Archived from the original on 12 April 2022. Retrieved 14 April 2022.
- "DCVMN". Developing Countries Vaccine Manufacturers Network. Archived from the original on 26 April 2022. Retrieved 26 April 2022.
- Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. (April 2021). "Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021" (PDF). MMWR Morb Mortal Wkly Rep. 70 (13): 495–500. doi:10.15585/mmwr.mm7013e3. PMC 8022879. PMID 33793460. Archived (PDF) from the original on 28 August 2021. Retrieved 9 June 2021.
- "When You've Been Fully Vaccinated". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 28 July 2021. Retrieved 29 April 2021.
- "COVID vaccines: Widening inequality and millions vulnerable". United Nations. 19 September 2021. Archived from the original on 31 December 2021. Retrieved 30 October 2021.
- "Impact of vaccine inequity on economic recovery". UN Development program. Archived from the original on 3 November 2021. Retrieved 30 October 2021.
- Elliott L (5 October 2021). "IMF cuts global economic forecast as pandemic 'hobbles' growth". The Guardian. Archived from the original on 27 October 2021. Retrieved 6 October 2021.
- "Refugees face dire consequences from COVID-19 underfunding, UNHCR warns". United Nations. 17 September 2021. Archived from the original on 30 October 2021. Retrieved 30 October 2021.
- Azar A (4 February 2020). "Notice of Declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID-19". Archived from the original on 25 April 2020. Retrieved 22 April 2020.
- Lintern S (2 December 2020). "Pfizer given protection from legal action over coronavirus vaccine by UK government". The Independent. Archived from the original on 5 May 2021. Retrieved 8 May 2021.
- "Questions and Answers: Conditional Marketing Authorisation of COVID-19 Vaccines in the EU". European Commission. 11 December 2020. Question: What is the difference in liability between EU Conditional Marketing Authorisation vs Emergency Use Authorisations?. Archived from the original on 4 October 2021. Retrieved 29 December 2020.
- "EMA recommends standard marketing authorizations for Comirnaty and Spikevax COVID-19 vaccines". European Medicines Agency. 16 September 2022. Archived from the original on 16 September 2022. Retrieved 7 October 2022.
- Haahr T (7 September 2020). "COVID-19: MEPs want safe vaccines, full transparency and liability for companies". European Parliament. Ms. Gallina stressed negotiations with companies had been difficult but underlined that those companies developing and manufacturing COVID-19 vaccines would indeed be liable according to current laws, and if something goes wrong, they could be taken to court. This also goes for compensation for hidden defects. Archived from the original on 13 October 2021. Retrieved 29 December 2020.
- "Investigation: Drugmaker 'bullied' Latin American nations". Al Jazeera. 11 March 2021. Archived from the original on 31 October 2021. Retrieved 15 June 2021.
- Barcellos R (13 May 2021). "Carlos Murillo diz que cláusulas criticadas pelo Brasil valem em 110 países" [Carlos Murillo says critical clauses for Brazil are valid in 110 countries]. CNN Brasil (in Portuguese). Archived from the original on 28 June 2021. Retrieved 15 June 2021.
- "Governor Ron DeSantis Petitions Florida Supreme Court for Statewide Grand Jury on COVID-19 Vaccines and Announces Creation of the Public Health Integrity Committee". www.flgov.com. Archived from the original on 14 December 2022. Retrieved 14 December 2022.
- "Florida governor seeks grand jury investigation into Covid vaccines". www.theguardian.com. 13 December 2022. Archived from the original on 13 December 2022. Retrieved 14 December 2022.
- "Blackwater founder Prince takes role in COVID vaccine venture". Reuters. 4 June 2021. Archived from the original on 9 October 2021. Retrieved 4 June 2021.
- "A Covid pass takes France by storm". WLFI News. Archived from the original on 20 September 2021. Retrieved 20 September 2021.
whatdotheyknow.com
whitehouse.gov
- "National COVID-19 Preparedness Plan" (PDF). The White House. March 2022. pp. 9, 21, 29. Archived from the original (PDF) on 26 March 2022. Retrieved 29 March 2022.
who.int
who.int
- "The CanSino Biologics Ad5-nCoV-S [recombinant] COVID-19 vaccine: What you need to know". www.who.int. Retrieved 12 July 2024.
- "Background document on the mRNA-1273 vaccine (Moderna) against COVID-19". World Health Organization (WHO). Archived from the original on 26 January 2022. Retrieved 23 January 2022.
- "Bacille Calmette-Guérin (BCG) vaccination and COVID-19". World Health Organization (WHO). 12 April 2020. Archived from the original on 30 April 2020. Retrieved 1 May 2020.
- "Access to COVID-19 Tools (ACT) Accelerator" (PDF). World Health Organization (WHO). 24 April 2020. Archived (PDF) from the original on 25 April 2020. Retrieved 1 February 2021.
- "The ACT-Accelerator: frequently asked questions (FAQ)". World Health Organization (WHO). 2020. Archived from the original on 4 May 2021. Retrieved 16 December 2020.
- "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020.
It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months, and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
- "AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine". World Health Organization (WHO). Archived from the original on 28 November 2021. Retrieved 28 November 2021.
- "World Health Organization timeline – COVID-19". World Health Organization (WHO). 27 April 2020. Archived from the original on 29 April 2020. Retrieved 2 May 2020.
- "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020.
It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
- "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020.
It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. The World Health Organization (WHO) is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
- "WHO, UN set out steps to meet world COVID vaccination targets". World Health Organization (WHO). 7 October 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
- Adhanom Ghebreyesus T (18 January 2021). "WHO Director-General's opening remarks at 148th session of the Executive Board". World Health Organization (WHO). Archived from the original on 12 November 2021. Retrieved 25 January 2021.
- "First Meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries". World Health Organization (WHO). 30 June 2021. Archived from the original on 19 October 2021. Retrieved 5 July 2021.
apps.who.int
- Background document on the mRNA-1273 vaccine (Moderna) against COVID-19 (Report). World Health Organization (WHO). February 2021. hdl:10665/339218. WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1. Archived from the original on 13 June 2021. Retrieved 24 July 2021.
wikidata.org
wlfi.com
- "A Covid pass takes France by storm". WLFI News. Archived from the original on 20 September 2021. Retrieved 20 September 2021.
worldcat.org
search.worldcat.org
- Beaumont P (18 November 2020). "Covid-19 vaccine: who are countries prioritising for first doses?". The Guardian. ISSN 0261-3077. Archived from the original on 18 January 2021. Retrieved 26 December 2020.
- Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. ISSN 0066-4219. PMID 34637324. S2CID 238747462.
- Park KS, Sun X, Aikins ME, Moon JJ (February 2021). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews. 169: 137–151. doi:10.1016/j.addr.2020.12.008. ISSN 0169-409X. PMC 7744276. PMID 33340620.
- Johnson CY, Mufson S (11 June 2020). "Can old vaccines from science's medicine cabinet ward off coronavirus?". The Washington Post. ISSN 0190-8286. Archived from the original on 11 June 2020. Retrieved 31 December 2020.
- Sanger DE, Kirkpatrick DD, Zimmer C, Thomas K, Wee SL (2 May 2020). "With Pressure Growing, Global Race for a Vaccine Intensifies". The New York Times. ISSN 0362-4331. Archived from the original on 11 May 2020. Retrieved 2 May 2020.
- Wee SL (4 May 2020). "China's coronavirus vaccine drive empowers a troubled industry". The New York Times. ISSN 0362-4331. Archived from the original on 4 May 2020. Retrieved 4 May 2020.
- Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
- Kramer AE (19 September 2020). "Russia Is Slow to Administer Virus Vaccine Despite Kremlin's Approval". The New York Times. ISSN 0362-4331. Archived from the original on 27 September 2020. Retrieved 28 September 2020.
- Schreiber M, Chayka K, Chayka K, Beyerstein L, Beyerstein L, Wilson J, et al. (1 July 2021). "The Delta Covid Variant's Urgent Message for America". The New Republic. ISSN 0028-6583. Archived from the original on 28 August 2021. Retrieved 28 October 2021.
- Stein C, Nassereldine H, Sorensen RJ, Amlag JO, Bisignano C, Byrne S, et al. (February 2023). "Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis". The Lancet. 401 (10379): 833–842. doi:10.1016/S0140-6736(22)02465-5. ISSN 0140-6736. PMC 9998097. PMID 36930674.
- Payne AB (2024). "Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023". MMWR. Morbidity and Mortality Weekly Report. 73 (1): 16–23. doi:10.15585/mmwr.mm7301a4. ISSN 0149-2195. PMC 10794061. PMID 38206877. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
- Weintraub R, Yadav P, Berkley S (2 April 2020). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. Archived from the original on 9 June 2020. Retrieved 9 June 2020.
- Gartner A, Roberts L (3 May 2020). "How close are we to a coronavirus vaccine? Latest news on UK trials". The Telegraph. ISSN 0307-1235. Archived from the original on 4 May 2020. Retrieved 3 May 2020.
- Goodman PS, Mandavilli A, Robbins R, Stevis-Gridneff M (15 May 2021). "What Would It Take to Vaccinate the World Against Covid?". The New York Times. ISSN 0362-4331. Archived from the original on 15 May 2021. Retrieved 17 May 2021.
wsj.com
- Loftus P, Hopkins JS, Pancevski B (17 November 2020). "Moderna and Pfizer Are Reinventing Vaccines, Starting With Covid". The Wall Street Journal. Archived from the original on 6 November 2021. Retrieved 4 October 2021.
x.com
- Sputnik V [@sputnikvaccine] (6 May 2021). "Introducing a new member of the Sputnik family - a single dose Sputnik Light! It's a revolutionary 1-shot COVID-19 vaccine with the 80% efficacy - higher than many 2-shot vaccines. Sputnik Light will double vaccination rates and help to handle epidemic peaks https://t.co/BCybe8yYWU" (Tweet). Archived from the original on 8 May 2022. Retrieved 8 December 2022 – via Twitter.
youtube.com
- EMA (7 April 2021). EMA press conference 7th April — Conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of COVID-19 Vaccine AstraZeneca and thromboembolic events. European Medicines Agency (EMA). Archived from the original on 7 April 2021. Retrieved 7 April 2021 – via Youtube.
- Offit P (13 February 2021). "TWiV 720: With vaccines, Offit is on it". This Week in Virology Podcast. Vincent Racaniello Youtube Channel. Archived from the original on 25 May 2021. Retrieved 14 July 2021.